Invitae (NVTAQ) 10-K 28 Feb 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Feb. 22, 2019	Jun. 29, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	Invitae Corp
Entity Central Index Key	1,501,134
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Trading Symbol	NVTA
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Common Stock, Shares Outstanding		76,811,562
Entity Public Float			$ 477.8
Document Fiscal Year Focus	43,465
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 112,158	$ 12,053
Marketable securities	13,727	52,607
Accounts receivable	26,296	10,422
Prepaid expenses and other current assets	13,258	11,599
Total current assets	165,439	86,681
Property and equipment, net	27,886	30,341
Restricted cash	6,006	5,406
Marketable securities, non-current	0	5,983
Intangible assets, net	30,469	35,516
Goodwill	50,095	46,575
Other assets	3,064	576
Total assets	282,959	211,078
Current liabilities:
Accounts payable	7,812	8,606
Accrued liabilities	26,563	22,742
Capital lease obligation, current portion	1,937	2,039
Total current liabilities	36,312	33,387
Capital lease obligation, net of current portion	1,375	3,373
Debt	74,477	39,084
Other long-term liabilities	8,956	13,440
Total liabilities	121,120	89,284
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value: 20,000 shares authorized; 3,459 shares issued and outstanding as of December 31, 2018 and 2017	0	0
Common stock, $0.0001 par value: 400,000 shares authorized; 75,481 and 53,597 shares issued and outstanding as of December 31, 2018 and 2017, respectively	8	5
Accumulated other comprehensive loss	(5)	(171)
Additional paid-in capital	678,548	520,558
Accumulated deficit	(516,712)	(398,598)
Total stockholders’ equity	161,839	121,794
Total liabilities and stockholders’ equity	$ 282,959	$ 211,078

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	20,000,000	20,000,000
Preferred stock, issued (in shares)	3,459,000	3,459,000
Preferred stock, outstanding (in shares)	3,459,000	3,459,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	400,000,000	400,000,000
Common stock, issued (in shares)	75,481,000	53,597,000
Common stock, outstanding (in shares)	75,481,000	53,597,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue:
Total revenue	$ 147,699	$ 68,221	$ 25,048
Costs and operating expenses:
Cost of revenue	80,105	50,142	27,878
Research and development	63,496	46,469	44,630
Selling and marketing	74,428	53,417	28,638
General and administrative	52,227	39,472	24,085
Total costs and operating expenses	270,256	189,500	125,231
Loss from operations	(122,557)	(121,279)	(100,183)
Other income (expense), net	(2,568)	(303)	348
Interest expense	(7,030)	(3,654)	(421)
Net loss before taxes	(132,155)	(125,236)	(100,256)
Income tax benefit	(2,800)	(1,856)	0
Net loss	$ (129,355)	$ (123,380)	$ (100,256)
Net loss per share, basic and diluted (in dollars per share)	$ (1.94)	$ (2.65)	$ (3.02)
Shares used in computing net loss per share, basic and diluted (in shares)	66,747	46,512	33,176
Test revenue
Revenue:
Total revenue	$ 144,560	$ 65,169	$ 24,840
Other revenue
Revenue:
Total revenue	$ 3,139	$ 3,052	$ 208

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement of Comprehensive Income [Abstract]
Net loss	$ (129,355)	$ (123,380)	$ (100,256)
Other comprehensive income (loss):
Unrealized income (loss) on available-for-sale marketable securities, net of tax	166	(171)	15
Comprehensive loss	$ (129,189)	$ (123,551)	$ (100,241)

Consolidated Statements of Conv

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at the beginning of the period at Dec. 31, 2015	$ 138,376		$ 4	$ 313,349	$ (15)	$ (174,962)
Balance at the beginning of the period (in shares) at Dec. 31, 2015		0	31,935
Increase (Decrease) in Stockholders' Deficit
Common stock issued on exercise of stock options	744			744
Options exercised (in shares)			244
Common stock issued pursuant to vesting of restricted stock units	(1)		$ (1)
Common stock issued pursuant to vesting of restricted stock units (in shares)			157
Common stock issued pursuant to employee stock purchase plan	2,391			2,391
Common stock issued pursuant to employee stock purchase plan (in shares)			370
Common stock issued in connection with initial public offering, net of offering costs	47,102		$ 1	47,101
Common stock issued in connection with initial public offering, net of offering costs (in shares)			8,433
Vesting of common stock related to early exercise of options	4			4
Vesting of common stock related to early exercise of options (in shares)			5
Stock-based compensation expense	10,699			10,699
Unrealized income (loss) on available-for-sale marketable securities, net of tax	15				15
Net loss	(100,256)					(100,256)
Balance at the end of the period at Dec. 31, 2016	99,074		$ 4	374,288		(275,218)
Balance at the end of the period (in shares) at Dec. 31, 2016		0	41,144
Increase (Decrease) in Stockholders' Deficit
Options exercised (in shares)			387
Common stock issued pursuant to vesting of restricted stock units (in shares)			925
Common stock issued pursuant to employee stock purchase plan	2,635			2,635
Common stock issued pursuant to employee stock purchase plan (in shares)			379
Stock-based compensation expense	18,832			18,832
Unrealized income (loss) on available-for-sale marketable securities, net of tax	(171)				(171)
Net loss	(123,380)					(123,380)
Common and convertible preferred stock issued in private placement, net of offering costs	68,897		$ 1	68,896
Common and convertible preferred stock issued in private placement, net of offering costs (in shares)		3,459	5,188
Common stock issued on exercise of stock options, net	1,706			1,706
Common stock issued pursuant to acquisition-related transaction bonus (in shares)			4
Common stock issued pursuant to exercises of warrants	1,381			1,381
Common stock issued pursuant to exercises of warrants (in shares)			232
Common stock issued pursuant to business combinations	50,808			50,808
Common stock issued pursuant to business combinations (in shares)			5,176
Common stock issued to settle assumed liabilities	1,272			1,272
Common stock issued to settle assumed liabilities (in shares)			162
Warrants issued pursuant to the 2017 Loan Agreement	740			740
Balance at the end of the period at Dec. 31, 2017	121,794		$ 5	520,558	(171)	(398,598)
Balance at the end of the period (in shares) at Dec. 31, 2017		3,459	53,597
Increase (Decrease) in Stockholders' Deficit
Options exercised (in shares)			351
Common stock issued pursuant to vesting of restricted stock units (in shares)			1,369
Common stock issued pursuant to employee stock purchase plan	3,231			3,231
Common stock issued pursuant to employee stock purchase plan (in shares)			566
Common stock issued in connection with initial public offering, net of offering costs	112,441		$ 3	112,438
Common stock issued in connection with initial public offering, net of offering costs (in shares)			17,103
Stock-based compensation expense	20,850			20,850
Unrealized income (loss) on available-for-sale marketable securities, net of tax	166				166
Net loss	(129,355)					(129,355)
Common stock issued on exercise of stock options, net	2,741			2,741
Common stock issued pursuant to exercises of warrants	6,539			6,539
Common stock issued pursuant to exercises of warrants (in shares)			1,099
Common stock issued pursuant to business combinations	6,455			6,455
Common stock issued pursuant to business combinations (in shares)			1,022
Warrants issued pursuant to the 2017 Loan Agreement	383			383
Common stock issued pursuant to Securities Purchase Agreement (see Note 9)	5,353			5,353
Common stock issued pursuant to debt financing (in shares)			374
Balance at the end of the period at Dec. 31, 2018	$ 161,839		$ 8	$ 678,548	$ (5)	$ (516,712)
Balance at the end of the period (in shares) at Dec. 31, 2018		3,459	75,481

Consolidated Statements of Co_2

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement of Stockholders' Equity [Abstract]
Offering costs	$ 6,183	$ 4,599	$ 3,498

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (129,355,000)	$ (123,380,000)	$ (100,256,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	13,540,000	9,181,000	6,553,000
Stock-based compensation	20,850,000	19,221,000	10,699,000
Impairment losses	2,925,000	0	0
Remeasurements of liabilities associated with business combinations	362,000	1,810,000	0
Benefit from income taxes	(2,862,000)	(1,856,000)	0
Debt extinguishment costs	(5,266,000)	0	0
Other	806,000	404,000	1,341,000
Changes in operating assets and liabilities, net of effects of business combination:
Accounts receivable	(5,291,000)	(1,963,000)	(843,000)
Prepaid expenses and other current assets	(1,445,000)	(641,000)	(1,149,000)
Other assets	(163,000)	(185,000)	1,465,000
Accounts payable	(417,000)	(535,000)	(111,000)
Accrued expenses and other liabilities	3,564,000	(37,000)	5,984,000
Net cash used in operating activities	(92,220,000)	(97,981,000)	(76,317,000)
Cash flows from investing activities:
Purchases of marketable securities	(9,680,000)	(101,867,000)	(90,236,000)
Proceeds from sales of marketable securities	19,965,000	0	0
Proceeds from maturities of marketable securities	32,458,000	68,768,000	117,922,000
Acquisition of businesses, acquired cash	0	2,821,000	0
Purchases of property and equipment	(5,970,000)	(6,675,000)	(11,625,000)
Other	(1,000,000)	0	0
Net cash provided by (used in) investing activities	35,773,000	(36,953,000)	16,061,000
Cash flows from financing activities:
Proceeds from public offering of common stock, net of issuance costs	112,441,000	0	47,102,000
Proceeds from issuance of common stock	17,511,000	74,619,000	3,134,000
Net proceeds from issuance of debt	93,909,000	39,661,000	7,500,000
Payments for debt extinguishment costs	(4,609,000)	0	0
Loan payments	(60,000,000)	(30,457,000)	(2,438,000)
Capital lease principal payments	(2,100,000)	(2,952,000)	(1,589,000)
Net cash provided by financing activities	157,152,000	80,871,000	53,709,000
Net increase (decrease) in cash, cash equivalents and restricted cash	100,705,000	(54,063,000)	(6,547,000)
Cash, cash equivalents and restricted cash at beginning of period	17,459,000	71,522,000	78,069,000
Cash, cash equivalents and restricted cash at end of period	118,164,000	17,459,000	71,522,000
Supplemental cash flow information:
Interest paid	6,231,000	2,852,000	421,000
Supplemental cash flow information of non-cash investing and financing activities:
Equipment acquired through capital leases	0	6,789,000	0
Purchases of property and equipment in accounts payable and accrued liabilities	510,000	200,000	1,644,000
Amounts related to co-development agreement in other assets and accrued liabilities	2,000,000	0	0
Warrants issued pursuant to 2017 Loan Agreement	383,000	740,000	0
Common stock issued for acquisition of businesses	6,445,000	50,808,000	0
Consideration payable for acquisition of businesses	0	13,276,000	0
Common stock issued to settle assumed liabilities	$ 0	$ 1,272,000	$ 0

Organization and description of

Organization and description of business	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and description of business	Organization and description of business Invitae Corporation (the “Company”) was incorporated in the State of Delaware on January 13, 2010, as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. The Company utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s headquarters and main production facility is located in San Francisco, California. The Company currently has more than 20,000 genes in production and provides a variety of diagnostic tests that can be used in multiple indications. The Company’s tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disord ers, pediatric disorders, metabolic disorders and other hereditary conditions. In addition, and as a result of the acquisitions of Good Start Genetics ("Good Start") in August 2017 and CombiMatrix Corporation ("CombiMatrix") in November 2017, the C ompany’s services also include screening and testing in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders. The Company operates in one

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Principles of consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company bases these estimates on historical and anticipated results, trends and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates and assumptions. Significant estimates and assumptions made by management include the determination of: • revenue recognition (See Note 3, “Revenue, accounts receivable and deferred revenue” for further information); • the fair value of assets acquired and liabilities assumed for business combinations; • the fair value of goodwill and intangible assets; • the recoverability of long-lived assets; • stock-based compensation expense and the fair value of awards issued; and • income tax uncertainties. Concentrations of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash and cash equivalents are held by financial institutions in the United States. Such deposits may exceed federally insured limits. Significant customers are those that represent 10% or more of the Company’s total revenue for each year presented on the statements of operations. For the significant customer, revenue as a percentage of total revenue were as follows: December 31, Customers 2018 2017 2016 Medicare 22 % 13 % 11 % Medicare represented 21% and 13% of accounts receivable as of December 31, 2018 and 2017 . Cash, cash equivalents, and restricted cash The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and U.S. government agency securities. Restricted cash consists of money market funds that serve as collateral for security deposits for the Company’s facility lease and sublease agreements and collateral for a credit card agreement at one of the Company’s financial institutions. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands): December 31, 2018 December 31, 2017 Cash and cash equivalents $ 112,158 $ 12,053 Restricted cash 6,006 5,406 Total cash, cash equivalents and restricted cash $ 118,164 $ 17,459 Marketable securities All marketable securities have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. Short-term marketable securities have maturities less than 365 days at the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest and other income (expense), net. Accounts receivable The Company receives payment for its tests from partners, patients, institutional customers and third-party payers. See Note 3, "Revenue, accounts receivable and deferred revenue" for further information. Inventory The Company maintains test reagents and other consumables primarily used in sample collection kits which are valued at the lower of cost or market value. Cost is determined using actual costs on a first-in, first-out basis. The Company's inventory was $8.3 million and $5.4 million as of December 31, 2018 and 2017 , respectively, and was recorded in prepaid expenses and other current assets in the Company's consolidated balance sheets. Business combinations The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under Financial Accounting Standards Board (“FASB") Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity , the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company remeasures this liability each reporting period and records changes in the fair value as a component of operating expenses. Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company’s operating results from the date of acquisition. Intangible assets Amortizable intangible assets include trade names, non-compete agreements, developed technology and customer relationships acquired as part of business combinations. Customer relationships are amortized on an accelerated basis, utilizing free cash flows, over periods ranging from five to 11 years . All other intangible assets subject to amortization are amortized using the straight-line method over their estimated useful lives ranging from two to 15 years . All intangible assets subject to amortization are reviewed for impairment in accordance with ASC 360, Property, Plant and Equipment. Goodwill In accordance with ASC 350, Intangibles-Goodwill and Other (“ASC 350”), the Company’s goodwill is not amortized but is tested for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Under ASC 350, the Company performs annual impairment reviews of its goodwill balance during the fourth fiscal quarter. In testing for impairment, the Company compares the fair value of its reporting unit to its carrying value including the goodwill of that unit. If the carrying value, including goodwill, exceeds the reporting unit’s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit’s fair value. The loss recognized cannot exceed the total amount of goodwill allocated to that reporting unit. The Company did not incur any goodwill impairment losses in any of the periods presented. Leases The Company rents its facilities under operating lease agreements and recognizes related rent expense on a straight-line basis over the term of the applicable lease agreement. Some of the lease agreements contain rent holidays, scheduled rent increases, lease incentives, and renewal options. Rent holidays and scheduled rent increases are included in the determination of rent expense to be recorded over the lease term. Lease incentives are recognized as a reduction of rent expense on a straight-line basis over the term of the lease. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The Company recognizes rent expense beginning on the date it obtains the legal right to use and control the leased space. Property and equipment, net Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight‑line method over the estimated useful lives of the assets, generally between three and seven years . Leasehold improvements are amortized using the straight‑line method over the shorter of the estimated useful life of the asset or the term of the lease. Amortization expense of assets acquired through capital leases is included in depreciation and amortization expense in the consolidated statements of operations. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized. The estimated useful lives of property and equipment are as follows: Furniture and fixtures 7 years Automobiles 7 years Laboratory equipment 5 years Computer equipment 3 years Software 3 years Leasehold improvements Shorter of lease term or estimated useful life Long‑lived assets The Company reviews long‑lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows or other appropriate measures of fair value. Other than impairment losses of $1.0 million in 2016 relating to leasehold improvements and to the shutdown of the Company’s Chilean operations, there were no long-lived asset impairment losses recorded for any period presented. All impairment losses were charged to general and administrative expense. Variable interest entity The Company had a variable interest in a variable interest entity (“VIE”) through an investment in convertible notes issued by the VIE. The convertible notes do not provide the Company with voting rights in the VIE or with power to direct the activities of the VIE which most significantly affect its economic performance. The Company is not the VIE’s primary beneficiary and it does not consolidate the VIE. Fair value of financial instruments The Company’s financial instruments consist principally of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities, capital leases and debt. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to the Company, the carrying value of capital leases and debt approximate their fair values. Revenue recognition The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers. Test revenue is generated primarily from the sale of tests that provide analysis and associated interpretation of the sequencing of parts of the genome. Other revenue consists primarily of revenue from genome network subscription services which is recognized on a straight-line basis over the subscription term, and revenue from collaboration agreements. Cost of revenue Cost of revenue reflects the aggregate costs incurred in delivering the genetic testing results to clinicians and includes expenses for personnel-related costs including stock-based compensation, materials and supplies, equipment and infrastructure expenses associated with testing and allocated overhead including rent, equipment depreciation and utilities. Income taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Stock-based compensation The Company measures its stock-based payment awards made to employees and directors based on the estimated fair values of the awards and recognizes the compensation expense over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards and employee stock purchase plan (“ESPP”) purchases. The fair value of restricted stock unit (“RSU”) awards with time-based vesting terms is based on the grant date share price. The Company grants performance-based restricted stock unit (“PRSU”) awards to certain employees which vest upon the achievement of certain performance conditions, subject to the employees’ continued service relationship with the Company. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment. The Company recognizes such compensation expense on an accelerated vesting method. Stock-based compensation expense for awards without a performance condition is recognized using the straight-line method. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company’s stock-based compensation is reduced for estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company accounts for compensation expense related to stock options granted to non-employees based on fair values estimated using the Black-Scholes option-pricing model. Stock options granted to non-employees are re-measured at each reporting date until the award is vested. The Company accounts for stock issued as compensation in connection with business combinations based on the fair value of the Company’s common stock on the date of issuance. Advertising Advertising expenses are expensed as incurred. The Company incurred advertising expenses of $0.6 million , $0.6 million and $0.5 million during the years ended December 31, 2018 , 2017 and 2016 , respectively. Comprehensive loss Comprehensive loss is composed of two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity, but are excluded from net loss. The Company’s other comprehensive income (loss) consists of unrealized gains or losses on investments in available-for-sale securities. Net loss per share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities, consisting of preferred stock, options to purchase common stock, common stock warrants, RSUs and PRSUs, are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per share because their effect would be antidilutive for all periods presented. Recent accounting pronouncements The Company evaluates all Accounting Standards Updates (“ASUs”) issued by the FASB for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s consolidated financial statements. Recently issued accounting pronouncements not yet adopted In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 , which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Accounting Standards Codification ("ASC") 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January 1, 2020. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) , which replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019, with early adoption permitted for the fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and in July 2018 issued ASU 2018-10 , Codification Improvements to Topic 842, Leases and ASU 2018-11 , Leases (Topic 842): Targeted Improvements (the foregoing ASUs collectively referred to as “Topic 842”). Under the new guidance, lessees are required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) at the commencement date and also requires expanded disclosures about leasing arrangements. Topic 842 is effective for annual and interim periods beginning on or after December 15, 2018 and early adoption is permitted. Entities may initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is evaluating the final effect that Topic 842 and related standards will have on its consolidated financial statements, related disclosures and ongoing financial reporting, but expects implementation of Topic 842 to result in the recognition of material right of use assets and corresponding lease liabilities in its consolidated balance sheets as of the implementation of Topic 842 on January 1, 2019, principally relating to facilities leases. The Company does not have any material embedded leases and the implementation of Topic 842 is primarily focused on the treatment of the Company's previously identified leases. As of December 31, 2018, the Company's total future undiscounted capital lease payments were $3.5 million and future undiscounted non-cancelable minimum operating lease payments, net of subleases were $78.4 million Recently adopted accounting pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), designed to enable users of financial statements to better understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. On January 1, 2018, the Company adopted the provisions of Topic 606 using the modified retrospective method. From adoption to date, the Company has recognized all its revenue from contracts with customers within the scope of Topic 606. In connection with the adoption, the Company recognized the cumulative effect of initially applying this standard as an adjustment to retained earnings on the date of adoption. Comparative information prior to the date of adoption has not been restated and continues to be reported under the accounting standards in effect for those periods. In connection with the adoption of Topic 606, the Company amended its revenue recognition policy to provide for the recognition of certain variable consideration related to diagnostic tests that was previously deferred pending cash collection. Under Topic 606, the Company records variable consideration based on an estimate of the consideration to which it will be entitled. The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers. Diagnostic tests The majority of the Company’s revenue is generated from genetic testing services that provide analysis and associated interpretation of the sequencing of parts of the genome. Test orders are placed under signed requisitions, and the Company often enters into contracts with institutions (e.g., hospitals and clinics) and insurance companies that include pricing provisions under which such tests are billed. Billing terms are generally net thirty days. While the transaction price of diagnostic tests is originally established either via contract or pursuant to the Company’s standard list price, the Company often provides concessions for tests billed to insurance carriers, and therefore the transaction price for patient insurance-billed tests is considered to be variable and revenue is recognized based on an estimate of the consideration to which the Company will be entitled at an amount for which it is probable that a reversal of cumulative consideration will not occur. Making these estimates requires significant judgments based upon such factors as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. These judgments are reviewed quarterly and revenue recognized is updated, as necessary, until the Company’s obligations are fully settled. In connection with some diagnostic test orders, the Company offers limited re-requisition rights (“Re-Requisition Rights”) that are considered distinct at contract inception, and therefore certain diagnostic test orders contain two performance obligations, the performance of the original test and the Re-Requisition Rights. When Re-Requisition Rights are granted, the Company allocates the transaction price to each performance obligation based on the relative estimated standalone selling prices. In order to comply with loss contract rules, the allocations are adjusted, if necessary, to ensure the amount deferred for Re-Requisition Rights is no less than the estimated cost of fulfilling the Company’s related obligations. The Company looks to transfer of control in assessing timing of recognition of revenue in connection with each performance obligation. In general, revenue in connection with diagnostic tests is recognized upon delivery of the underlying clinical report or when the report is made available on the Company’s web portal. Outstanding performance obligations pertaining to orders received but for which the underlying report has not been issued are generally satisfied within a thirty-day period. Revenue in connection with Re-Requisition Rights is recognized as the rights are exercised or expire unexercised, which is generally within ninety days of initial deferral. Other contracts The Company also enters into collaboration and genome network contracts. Collaboration agreements provide customers with diagnostic testing and related data aggregation reporting services that are provided over the contract term. Collaboration revenue is recognized as the testing and reporting services are delivered to the customer. Genome network offerings consist of subscription services related to a proprietary software platform designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis and treatment of hereditary disease. Such services are recognized on a straight-line basis over the subscription periods.

Revenue, accounts receivable an

Revenue, accounts receivable and deferred revenue	12 Months Ended
	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue, accounts receivable and deferred revenue	Revenue, accounts receivable and deferred revenue As described in Note 2, "Summary of significant accounting policies," the Company adopted Topic 606 effective January 1, 2018. In connection with the adoption the Company utilized the following practical expedients and exemptions: • Certain information about remaining performance obligations is not disclosed because the underlying contracts have an original expected duration of one year or less. • Costs to obtain or fulfill a contract are expensed when incurred because the amortization period would have been one year or less. • No adjustments to promised consideration were made for financing as the Company expects, at contract inception, that the period between the transfer of a promised good or service and when the customer pays for that good or service will be one year or less. The adoption of Topic 606 resulted in a cumulative-effect adjustment to accounts receivable and accumulated deficit of $11.2 million as of January 1, 2018 primarily related to the recognition of uncollected diagnostic test variable consideration as of the date of adoption. Test revenue without adoption of Topic 606 for the year ended December 31, 2018 includes cash collections related to accounts receivable recorded as of January 1, 2018 in connection with the Topic 606 cumulative-effect adjustment. The effect of the adoption of Topic 606 on financial statement line items in the Company’s consolidated statement of operations for the year ended December 31, 2018 , and the Company’s consolidated balance sheet as of December 31, 2018 was as follows (in thousands, except per share amounts): Year Ended December 31, 2018 Without Effect of Adoption of Adoption As Reported Topic 606 Higher/(Lower) Test revenue $ 144,560 $ 144,222 $ 338 Net loss $ (129,355 ) $ (129,693 ) $ 338 Net loss per share, basic and diluted $ (1.94 ) $ (1.94 ) $ — As of December 31, 2018 Without Effect of Adoption of Adoption As Reported Topic 606 Higher/(Lower) Accounts receivable $ 26,296 $ 14,150 $ 12,146 Accumulated deficit $ (516,712 ) $ (528,291 ) $ 11,579 Stockholders' equity $ 161,839 $ 150,260 $ 11,579 Disaggregation of revenue Test revenue is generated from sales of diagnostic tests to three groups of customers: institutions, such as hospitals, clinics and partners; patients who pay directly; and patients’ insurance carriers. Amounts billed and collected, and the timing of collections, vary based on whether the payer is an institution, an insurance carrier or a patient. Other revenue consists principally of revenue recognized under collaboration and genome network agreements. The following table includes the Company’s revenues as disaggregated by payer category (in thousands): Year Ended December 31, 2018 2017 (1) Test revenue: Institutions $ 34,618 $ 17,238 Patient - direct 13,589 5,638 Patient - insurance 96,353 42,293 Total test revenue 144,560 65,169 Other revenue 3,139 3,052 Total revenue $ 147,699 $ 68,221 ___________________________________________________________________ (1) As noted above, prior period amounts are presented as originally reported based upon the accounting standards in effect for those periods. Included in revenue in the Company’s consolidated statements of operations for the year ended December 31, 2018 was $0.3 million that was included in deferred revenue at January 1, 2018. The Company recognizes revenue related to billings based on estimates of the amount that will ultimately be realized. The estimate of the transaction price of test revenue is based on many factors such as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. Cash collections for certain tests delivered may differ from rates originally estimated. As a result of new information, the Company updated its estimate of the amounts to be recognized for previously delivered tests which resulted in an additional $4.5 million of test revenue for the year ended December 31, 2018 . These changes in estimates decreased the Company’s loss from operations by $4.5 million and decreased basic and diluted net loss per share by approximately $0.07 for the year ended December 31, 2018 . Accounts receivable The majority of the Company’s accounts receivable represents amounts billed to institutions (e.g., hospitals, clinics) and estimated amounts to be collected from third-party insurance payers for test revenue recognized. Also included is amounts due under the terms of collaboration and genome network agreements for diagnostic testing and data aggregation reporting services provided and proprietary platform access rights transferred. Deferred revenues

Business combinations

Business combinations	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Business combinations	Business combinations AltaVoice On January 6, 2017, the Company acquired AltaVoice (formerly PatientCrossroads, Inc.), a privately-owned patient-centered data company with a global platform for collecting, curating, coordinating and delivering safeguarded data from patients and clinicians. The acquisition, complemented by several other strategic partnerships, expanded the Company's genome network, designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis, and treatment of hereditary disease. Pursuant to the terms of the Stock Purchase Agreement, the Company acquired all of the outstanding shares of AltaVoice for total purchase consideration of $12.4 million , payable in the Company’s common stock, as follows: (a) payment of $5.5 million through the issuance of 641,126 shares of the Company’s common stock; (b) payment of $5.0 million in the Company’s common stock, payable on March 31, 2018, with the common shares deliverable equal to $5.0 million divided by the trailing average share price of the Company’s common stock for the 30 days preceding March 31, 2018. This payment was made in April 2018 through the issuance of 716,332 shares of the Company's common stock; (c) payment of $5.0 million in the Company’s common stock, which was contingently payable on March 31, 2018 if a milestone based on a certain threshold of revenue was achieved during 2017, with the shares deliverable equal to $5.0 million divided by the trailing average share price of the Company’s common stock for the 30 days preceding March 31, 2018. As the foregoing milestone was not achieved, there was a new contingent milestone based on achieving a revenue target during 2017 and 2018. Since this new contingent milestone was achieved, on March 31, 2019, a payment of $5.0 million in the Company’s common stock will be payable. The actual payout is dependent upon meeting the 2017 and 2018 revenue targets (capped at $14.0 million ) times 75% less $5.5 million . This formula in effect caps the possible payout amount at $5.0 million in the Company’s common shares. The number of shares to be issued will be equal to the payout amount divided by the trailing average share price of the Company’s common stock for the 30 days preceding March 31, 2019. The first payment of $5.5 million was classified as equity. The second payment was discounted to $4.7 million as of the acquisition date, recorded as a liability, and was accreted to fair value at each reporting date until the extinguishment of the liability in April 2018. The third payment, representing contingent consideration, was determined to have a fair value of $2.2 million as of the acquisition date and was recorded as a liability. In accordance with ASC Topic 805, Business Combinations, the contingent consideration of $2.2 million was remeasured to fair value at each reporting date until the contingency was resolved, with changes in fair value recognized in earnings. For the second payment, the acquisition-date fair value was $4.7 million , and the Company recorded accretion gains (losses) of $1.6 million and $(0.2) million in other income (expense), net, for the years ended December 31, 2018 and 2017 , respectively. The accretion gains in 2018 resulted from an adjustment to the value of the second payment as of March 31, 2018, and principally reflected the difference between the value of the common shares deliverable, based upon the closing price of the Company’s stock on March 29, 2018, and the value per share used to calculate the number of common shares deliverable. The accretion losses in 2017 resulted from adjustments to the discounted value of the second payment, reflecting the passage of time. For the third payment, the acquisition-date fair value was $2.2 million , and the Company recorded remeasurement losses of $1.2 million and $1.6 million in general and administrative expense for the years ended December 31, 2018 and 2017 , respectively. The remeasurement losses in 2018 reflect updated estimations of fair value of the third payment, based upon achieving a revenue target during 2017 and 2018, as the milestone based on a certain threshold of revenue to be achieved during 2017 was not met. The principal inputs affecting those estimations have been updates to the Company’s revenue forecasts and the passage of time. Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands): Cash $ 54 Accounts receivable 274 Prepaid expense and other assets 52 Non-compete agreement 286 Developed technology 570 Customer relationships 3,389 Total identifiable assets acquired 4,625 Accounts payable (28 ) Deferred revenue (202 ) Accrued expenses (21 ) Deferred tax liability (1,422 ) Total liabilities assumed (1,673 ) Net identifiable assets acquired 2,952 Goodwill 9,432 Net assets acquired $ 12,384 Acquisition-related intangibles included in the above table are finite-lived. Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of ten years . All other acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands): Gross Purchased Intangible Assets Estimated Useful Life (in Years) Non-compete agreement $ 286 5 Developed technology 570 6 Customer relationships 3,389 10 $ 4,245 Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of AltaVoice resulted in $9.4 million of goodwill which the Company believes consists principally of expected synergies to be realized by combining capabilities, technology and data to accelerate the use of genetic information for the diagnosis and treatment of hereditary diseases. In accordance with ASC 350, goodwill will not be amortized but will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date. Ommdom On June 11, 2017, the Company acquired Ommdom, Inc. (“Ommdom”), a privately held company that develops, commercializes and sells hereditary risk assessment and management software, including CancerGene Connect, a cancer genetic counseling platform. The acquisition expanded Invitae’s suite of genome management offerings designed to help patients and clinicians use genetic information as part of mainstream medical care. CancerGene Connect is a platform for collecting and managing genetic family histories. Pursuant to the terms of a Stock Exchange Agreement, the Company acquired all of the outstanding shares of Ommdom for consideration of $6.1 million , payable entirely in the Company’s common stock. There was no cash consideration nor any contingent payments associated with the acquisition, other than a hold-back amount of $0.6 million . Per the terms of the agreement, the Company was obligated to issue shares of its common stock as follows: (a) payment of $5.5 million through the issuance of 600,108 shares of the Company’s common stock on the acquisition date; and (b) payment of $0.6 million through the issuance of 66,582 shares of the Company’s common stock, representing a hold-back amount, and payable on the twelve-month anniversary of the acquisition date. The first payment of $5.5 million was classified as equity. The second payment of $0.6 million was recorded as a stock payable liability on the acquisition date and was reclassified to equity upon the issuance of 66,582 shares of the Company’s common stock in June 2018. Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands): Cash $ 53 Accounts receivable 10 Prepaid expense and other assets 4 Trade name 13 Developed technology 2,335 Customer relationships 147 Total identifiable assets acquired 2,562 Accounts payable (16 ) Accrued expenses (17 ) Deferred tax liability (434 ) Total liabilities assumed (467 ) Net identifiable assets acquired 2,095 Goodwill 4,045 Net assets acquired $ 6,140 Finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands): Gross Purchased Intangible Assets Estimated Useful Life (in Years) Trade name $ 13 5 Developed technology 2,335 5 Customer relationships 147 5 $ 2,495 Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of Ommdom resulted in the recognition of $4.0 million of goodwill which the Company believes consists principally of expected synergies to be realized by expanding the Company’s suite of genome management offerings. In accordance with ASC 350, goodwill will not be amortized but rather will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date. Good Start Genetics On August 4, 2017, the Company acquired 100% of the fully diluted equity of Good Start, a privately held molecular diagnostics company focused on preimplantation and carrier screening for inherited disorders. The acquisition of Good Start was intended to further Invitae’s plan to create a comprehensive genetic information platform providing high-quality, affordable genetic information coupled with world-class clinical expertise to inform healthcare decisions throughout every stage of an individual’s life. The purchase consideration for the Good Start acquisition consisted of the assumption of the net liabilities of Good Start of $24.4 million at the acquisition date. Immediately subsequent to the acquisition of Good Start, the Company paid $18.4 million in cash to settle outstanding notes payable, accrued interest and related costs. In addition, and immediately subsequent to the acquisition, the Company settled outstanding convertible promissory notes payable through: (a) payment of $11.9 million through the issuance of 1,148,283 shares of the Company’s common stock; and (b) payment of $3.6 million through the issuance of 343,986 shares of the Company’s common stock, representing a hold-back amount payable on the one-year anniversary of the acquisition date. In September 2018, the Company issued 212,260 shares in partial payment of the hold-back amount payable. The remainder of the hold-back amount payable, approximately $1.3 million as of December 31, 2018, will be settled upon resolution of outstanding claims from Good Start customers, of which $0.6 million was settled in January 2019. Also in connection with the acquisition of Good Start and immediately subsequent to the acquisition, the Company paid bonuses to certain members of Good Start’s management team through: (a) payment of $0.9 million through the issuance of 83,025 shares of the Company’s common stock; and (b) payment of $0.4 million through the issuance of 37,406 shares of the Company’s common stock, representing a hold-back amount payable on the one-year anniversary of the acquisition date. In September 2018, the Company issued 27,784 shares in partial payment of the hold-back amount payable to settle bonuses to Good Start's management team. The remainder of the hold-back amount payable, approximately $0.2 million as of December 31, 2018, will be settled upon resolution of outstanding claims from Good Start customers, of which $0.1 million was settled in January 2019. These bonus payments were recorded as general and administrative expense. Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. At acquisition date, the Company also recorded $4.8 million as a provisional amount for a deferred tax liability because certain information and analysis related to Good Start’s historical net operating losses that could have affected the Company’s initial valuation was still being obtained or reviewed at that time. This provisional amount for the deferred tax liability was subsequently reversed during the fourth quarter of 2017 based on the results of further analysis of Good Start’s historical net operating losses. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands): Cash and restricted cash $ 1,381 Accounts receivable 2,246 Prepaid expense and other assets 1,579 Property and equipment 1,320 Trade name 460 Developed technology 5,896 Customer relationships 7,830 Total identifiable assets acquired 20,712 Accounts payable (5,418 ) Accrued expenses (6,802 ) Notes payable (17,904 ) Convertible promissory notes payable (15,430 ) Other liabilities (222 ) Total liabilities assumed (45,776 ) Net identifiable assets acquired (25,064 ) Goodwill 25,064 Net assets acquired $ — During the year ended December 31, 2018, the Company recorded adjustments to its accounting for the amount recorded as accounts receivable at acquisition. Accordingly, the fair value of accounts receivable was decreased by $0.7 million during the year ended December 31, 2018, with corresponding increases to goodwill. Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of eight years . All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands): Gross Purchased Intangible Assets Estimated Useful Life (in Years) Trade name $ 460 3 Developed technology 5,896 5 Customer relationships 7,830 8 $ 14,186 Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of Good Start resulted in the recognition of $25.1 million of goodwill which the Company believes consists principally of expected synergies to be realized by expanding the Company’s suite of genome management offerings. In accordance with ASC 350, goodwill will not be amortized but rather will be tested for impairment at least annually. Goodwill created as a result of the acquisition is not deductible for tax purposes. The Company has finalized its assessment of fair value of the assets and liabilities assumed at the acquisition date. CombiMatrix On November 14, 2017, the Company completed its acquisition of CombiMatrix in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of July 31, 2017 (the “Merger Agreement”), by and among the Company, Coronado Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and CombiMatrix, pursuant to which Merger Sub merged with and into CombiMatrix, with CombiMatrix surviving as a wholly owned subsidiary of the Company (the “Merger”). At the closing of the Merger, the Company issued shares of its common stock to (i) CombiMatrix’s common stockholders, at an exchange ratio of 0.8692 of a share of the Company’s common stock (the “Merger Exchange Ratio”) for each share of CombiMatrix common stock outstanding immediately prior to the Merger, (ii) CombiMatrix’s Series F preferred stockholders, at the Merger Exchange Ratio for each share of CombiMatrix common stock underlying Series F preferred stock outstanding immediately prior to the Merger, (iii) holders of outstanding and unexercised in-the-money CombiMatrix stock options, which were fully accelerated to the extent of any applicable vesting period and converted into the right to receive the number of shares of the Company’s common stock equal to the Merger Exchange Ratio multiplied by the number of shares of CombiMatrix common stock issuable upon exercise of such option, minus the number of shares of the Company’s common stock determined by dividing the aggregate exercise price for such option by $9.491 , and (iv) holders of outstanding and unsettled CombiMatrix restricted stock units, which were fully accelerated to the extent of any applicable vesting period and converted into the right to receive a number of shares of the Company’s common stock determined by multiplying the number of shares of CombiMatrix common stock that were subject to such restricted stock unit by the Merger Exchange Ratio. In addition, at the closing of the Merger, (a) all outstanding and unexercised out-of-the money CombiMatrix stock options were cancelled and terminated without the right to receive any consideration, (b) all CombiMatrix Series D Warrants and Series F Warrants outstanding and unexercised immediately prior to the closing of the Merger were assumed by the Company and converted into warrants to purchase the number of shares of the Company’s common stock determined by multiplying the number of shares of CombiMatrix common stock subject to such warrants by the Merger Exchange Ratio, and with the exercise price adjusted by dividing the per share exercise price of the CombiMatrix common stock subject to such warrants by the Merger Exchange Ratio, and (c) certain entitlements under CombiMatrix’s executive compensation transaction bonus plan (the “Transaction Bonus Plan”) were paid in shares of the Company’s common stock or RSUs to be settled in shares of the Company’s common stock. All outstanding and unexercised CombiMatrix Series A, Series B, Series C, Series E, and PIPE warrants were repurchased by CombiMatrix prior to closing pursuant to that certain CombiMatrix Common Stock Purchase Warrants Repurchase Agreement dated July 11, 2016. Pursuant to the Merger Agreement, the Company issued an aggregate of 2,703,389 shares of its common stock as follows: (a) payment of $20.5 million through the issuance of 2,611,703 shares of the Company’s common stock to holders of CombiMatrix common stock outstanding; (b) payment of $0.7 million through the issuance of 85,219 shares of the Company’s RSUs to holders of outstanding and unsettled CombiMatrix restricted stock units; (c) payment of $0.1 million through the issuance of 3,323 shares of the Company’s common stock to holders of outstanding and unexercised in-the-money CombiMatrix stock options; and (d) payment of $0.1 million through the issuance of 3,144 shares of the Company’s common stock to holders of CombiMatrix Series F preferred stock. In addition, and pursuant to the Merger Agreement, the Company issued warrants to purchase an aggregate of 2,077,273 shares of its common stock as follows: (a) payment of $7.4 million through the issuance of warrants to purchase a total of 1,739,689 shares of the Company’s common stock in exchange for all outstanding CombiMatrix Series F warrants; and (b) payment of $1,000 through the issuance of warrants to purchase a total of 337,584 shares of the Company’s common stock in exchange for all outstanding CombiMatrix Series D warrants. In connection with the acquisition of CombiMatrix, the Company paid bonuses to certain members of CombiMatrix’s management team through: (a) payment of $1.7 million through the issuance of common stock and RSUs totaling 214,976 shares of the Company’s common stock to settle payments pursuant to CombiMatrix’s executive compensation transaction bonus plan (the “Transaction Bonus Plan”), recorded as post-combination compensation expense and included in general and administrative expense; and (b) payment of $0.2 million through the issuance of 22,966 shares of the Company’s common stock to settle payments pursuant to the Transaction Bonus Plan, recorded as an assumed liability at the acquisition date. Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands): Cash and restricted cash $ 1,333 Accounts receivable 4,118 Prepaid expense and other assets 1,299 Property and equipment 437 Other assets - non current 30 Favorable leases 247 Trade name 103 Patent licensing agreement 496 Developed technology 3,162 Customer relationships 12,397 Total identifiable assets acquired 23,622 Accounts payable (276 ) Accrued expenses (3,925 ) Deferred tax liability (2,862 ) Other liabilities (180 ) Total liabilities assumed (7,243 ) Net identifiable assets acquired 16,379 Goodwill 11,554 Net assets acquired $ 27,933 During the year ended December 31, 2018, upon the completion of the Company's analysis of CombiMatrix's historical net operating losses, the Company recorded a deferred tax liability of $2.9 million with corresponding increases to goodwill. The $2.9 million net deferred tax liability represents the excess of the financial reporting over tax basis in acquired intangibles over the amount of CombiMatrix’s historical net operating loss carryovers that were determined to be available to offset future income due to change in ownership operating loss carryover limitation rules under Internal Revenue Code section 382. Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of eleven years . All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands): Gross Purchased Intangible Assets Estimated Useful Life (in Years) Favorable leases $ 247 2 Trade name 103 1 Patent licensing agreement 496 15 Developed technology 3,162 4 Customer relationships 12,397 11 $ 16,405 Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of CombiMatrix resulted in the recognition of $11.6 million

Goodwill and intangible assets

Goodwill and intangible assets	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible assets	Goodwill and intangible assets Goodwill Details of the Company’s goodwill for the year ended December 31, 2018 are as follows (in thousands): AltaVoice Ommdom Good Start CombiMatrix Total Balance as of December 31, 2017 $ 9,432 $ 4,045 $ 24,406 $ 8,692 $ 46,575 Goodwill adjustment — — 658 2,862 3,520 Balance as of December 31, 2018 $ 9,432 $ 4,045 $ 25,064 $ 11,554 $ 50,095 The goodwill adjustments were principally due to changes in the fair value of accounts receivable for Good Start as well as the recognition of a $2.9 million deferred tax liability for CombiMatrix resulting from the completion of the Company’s analysis of historical net operating losses. Intangible assets The following table presents details of the Company’s finite-lived intangible assets as of December 31, 2018 (in thousands): Cost Accumulated Amortization Net Weighted Average Useful Life (in Years) Weighted Average Estimated Remaining Useful Life (in Years) Customer relationships $ 23,763 $ (2,783 ) $ 20,980 10.0 8.6 Developed technology 11,963 (3,482 ) 8,481 4.8 3.4 Non-compete agreement 286 (114 ) 172 5.0 3.0 Trade name 576 (329 ) 247 2.7 1.4 Patent licensing agreement 496 (37 ) 459 15.0 13.9 Favorable leases 247 (117 ) 130 2.2 1.1 $ 37,331 $ (6,862 ) $ 30,469 8.2 6.8 Acquisition-related intangibles included in the above table are finite-lived. Customer relationships are being amortized on an accelerated basis, in proportion to estimated cash flows, over periods ranging from five to eleven years . All other acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are realized. Amortization expense was $5.0 million , $1.8 million , and nil for the years ended December 31, 2018 , 2017 , and 2016 , respectively. Intangible assets are carried at cost less accumulated amortization. Amortization expense is recorded to research and development, sales and marketing and general and administrative expense. The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of December 31, 2018 (in thousands): Amount 2019 $ 5,250 2020 5,525 2021 5,829 2022 4,124 2023 3,111 Thereafter 6,630 Total estimated future amortization expense $ 30,469

Balance sheet components

Balance sheet components	12 Months Ended
	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Balance sheet components	Balance sheet components Property and equipment, net Property and equipment consisted of the following (in thousands): December 31, 2018 December 31, 2017 Leasehold improvements $ 13,034 $ 12,623 Laboratory equipment 22,149 17,705 Equipment under capital lease 7,129 11,446 Computer equipment 4,723 4,023 Software 2,594 2,520 Furniture and fixtures 784 569 Automobiles 20 20 Construction-in-progress 1,962 965 Total property and equipment, gross 52,395 49,871 Accumulated depreciation and amortization (24,509 ) (19,530 ) Total property and equipment, net $ 27,886 $ 30,341 Depreciation expense was $8.5 million , $7.2 million and $6.6 million for the years ended December 31, 2018 , 2017 and 2016 , respectively. Accrued liabilities Accrued liabilities consisted of the following (in thousands): December 31, 2018 December 31, 2017 Accrued compensation and related expenses $ 7,917 $ 7,406 Deferred revenue 761 307 Liabilities associated with business combinations 6,460 9,497 Liability associated with co-development agreement 2,000 — Other 9,425 5,532 Total accrued liabilities $ 26,563 $ 22,742 Other long-term liabilities Other long-term liabilities consisted of the following (in thousands): December 31, 2018 December 31, 2017 Lease incentive obligation, non-current $ 3,280 $ 3,831 Deferred rent, non-current 5,495 5,153 Liabilities associated with business combinations — 3,779 Other non-current liabilities 181 677 Total other long-term liabilities $ 8,956 $ 13,440

Fair value measurements

Fair value measurements	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair value measurements	Fair value measurements Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The authoritative guidance establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is summarized as follows: Level 1—Observable inputs such as quoted prices (unadjusted) for identical instruments in active markets. Level 2—Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-derived valuations whose significant inputs are observable. Level 3—Unobservable inputs that reflect the reporting entity’s own assumptions. The following tables set forth the fair value of the Company’s consolidated financial instruments that were measured at fair value on a recurring basis (in thousands): December 31, 2018 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Level 1 Level 2 Level 3 Financial assets: Money market funds $ 93,934 $ — $ — $ 93,934 $ 93,934 $ — $ — Certificates of deposit 300 — — 300 — 300 — Commercial paper 10,908 — (1 ) 10,907 — 10,907 — U.S. treasury notes 9,990 — — 9,990 9,990 — — U.S. government agency securities 6,001 — (4 ) 5,997 — 5,997 — Total financial assets $ 121,133 $ — $ (5 ) $ 121,128 $ 103,924 $ 17,204 $ — Financial liabilities: Contingent consideration $ 4,998 $ — $ — $ 4,998 Total financial liabilities $ 4,998 $ — $ — $ 4,998 December 31, 2018 Reported as: Cash equivalents $ 101,395 Restricted cash 6,006 Marketable securities 13,727 Total cash equivalents, restricted cash, and marketable securities $ 121,128 Accrued liabilities $ 4,998 December 31, 2017 Amortized Gross Gross Estimated Level 1 Level 2 Level 3 Financial assets: Money market funds $ 5,998 $ — $ — $ 5,998 $ 5,998 $ — $ — Certificates of deposit 300 — — 300 300 — — U.S. treasury notes 12,010 — (19 ) 11,991 11,991 — — U.S. government agency securities 46,451 — (152 ) 46,299 — 46,299 — Total financial assets $ 64,759 $ — $ (171 ) $ 64,588 $ 18,289 $ 46,299 $ — Financial liabilities: Contingent consideration $ 3,779 $ — $ — $ 3,779 Total financial liabilities $ 3,779 $ — $ — $ 3,779 December 31, 2017 Reported as: Cash equivalents $ 592 Restricted cash 5,406 Marketable securities 58,590 Total cash equivalents, restricted cash, and marketable securities $ 64,588 Accrued liabilities $ 3,779 There were no transfers between Level 1, Level 2 and Level 3 during the periods presented. The total fair value of investments with unrealized losses at December 31, 2018 was $13.4 million . None of the available-for-sale securities held as of December 31, 2018 has been in a material continuous unrealized loss position for more than one year. At December 31, 2018 , unrealized losses on available-for-sale investments are not attributed to credit risk and are considered to be temporary. The Company believes it is more likely than not that investments in an unrealized loss position will be held until maturity or the recovery of the cost basis of the investment. To date, the Company has not identified any other-than-temporary declines in market value and thus has not recorded any impairment charges on its financial assets other than on the convertible notes which are described in Note 8, “Investment in privately held company.” At December 31, 2018 , the remaining contractual maturities of available-for-sale securities ranged from less than one to 4 months. For the years ended December 31, 2018 , 2017 and 2016 , there were no realized gains or losses on available-for-sale securities. The Company’s certificates of deposit, commercial paper, and debt securities of U.S. government agency entities are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third party data providers, including but not limited to benchmark yields, interest rate curves, reported trades, broker/dealer quotes and reference data. The following table presents the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands): Level 3 Contingent Consideration Liability Balance as of December 31, 2017 $ 3,779 Change in estimate of fair value 1,219 Balance as of December 31, 2018 $ 4,998 As of December 31, 2018 , the Company had a contingent obligation of up to $5.0 million payable in the Company’s common stock to the former owners of AltaVoice in conjunction with the Company’s acquisition of AltaVoice in January 2017. The contingency was dependent upon future revenues attributable to AltaVoice. If the revenue attributable to AltaVoice for the combined period of 2017 and 2018 was at least $10 million , the Company would make a payment of up to $5.0 million in the Company’s common stock in March 2019. The Company estimated the fair value of the contingent consideration at $2.2 million at the acquisition date in January 2017, based on a Monte Carlo simulation, as well as estimates of the 30-day trailing price of its stock at certain dates, its volatility assumptions and its revenue forecasts, all of which were significant inputs in the Level 3 measurement not supported by market activity. The value of the liability was subsequently remeasured to fair value at each reporting date. Changes in estimated fair value are recorded as general and administrative expense until the contingency is paid or expires. The change in the fair value of the contingent consideration between the acquisition date and December 31, 2018 was an increase of $2.8 million . The fair value of the Company’s outstanding debt is estimated using the net present value of future debt payments, discounted at an interest rate that is consistent with market interest rates, which is a Level 2 input. The carrying amount of the Company’s outstanding debt at December 31, 2018 approximated its fair value and as of December 31, 2017 , the Company's debt carrying amount and fair value were as follows (in thousands): December 31, 2017 Carrying Amount Fair Value Debt $ 39,084 $ 40,526

Investment in privately held co

Investment in privately held company Investment in privately held company	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Investment in privately held company	Investment in privately held company On March 15, 2018, the Company entered into a collaboration agreement with KEW, Inc. (“KEW”), a privately held comprehensive genomic profiling company . The Company determined it had a variable interest in a VIE through its investment in a convertible note issued by KEW . During the year ended December 31, 2018 , the Company incurred losses relating to this collaboration agreement with KEW of $2.9 million which were recognized in general and administrative expenses in the Company’s consolidated statements of operations. As of December 31, 2018

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies Operating leases In September 2015, the Company entered into a lease agreement for its headquarters and main production facility in San Francisco, California. This lease expires in July 2026 and the Company may renew the lease for an additional ten years . The Company has determined the lease term to be a ten-year period expiring in 2026. The lease term commenced when the Company took occupancy of the facility in February 2016. In connection with the execution of the lease, the Company provided a security deposit of approximately $4.6 million which is included in restricted cash in the Company’s consolidated balance sheets. Minimum annual rent under the lease is subject to increases based on stated rental adjustment terms. In addition, per the terms of the lease, the Company received a $5.2 million lease incentive in the form of reimbursement from the landlord for a portion of the costs of leasehold improvements the Company has made to the facility. The assets purchased with the lease incentive are included in property and equipment, net, in the Company’s consolidated balance sheets and the lease incentive is recognized as a reduction of rental expense on a straight-line basis over the term of the lease. At December 31, 2018 , all of the lease incentive had been utilized by the Company and all related reimbursements had been received from the landlord. Aggregate future minimum lease payments for this facility at December 31, 2018 were approximately $57.8 million . Future minimum payments under non-cancelable operating leases and future minimum payments to be received from non-cancelable subleases as of December 31, 2018 are as follows (in thousands): Amounts 2019 $ 10,948 2020 10,860 2021 11,109 2022 11,067 2023 8,898 Thereafter 25,715 Future non-cancelable minimum operating lease payments 78,597 Less: minimum payments to be received from non-cancelable subleases (174 ) Total future non-cancelable minimum operating lease payments, net $ 78,423 The following table summarizes rent expense related to non-cancelable operating leases (in thousands): Year Ended December 31, 2018 2017 2016 Rent expense $ 9,720 $ 8,950 $ 8,901 Sublease income 227 398 257 Rent expense, net of sublease income $ 9,493 $ 8,552 $ 8,644 Debt financing In March 2017, the Company entered into a Loan and Security Agreement (the “2017 Loan Agreement”) with a lender pursuant to which the Company borrowed an initial term loan of $40.0 million , and received net proceeds of approximately $39.7 million . Subject to certain conditions, the Company was eligible to borrow a second term loan pursuant to the 2017 Loan Agreement of $20.0 million in the first quarter of 2018 and did so in March 2018, receiving net proceeds of approximately $19.8 million . In February 2018 and June 2018, the Company entered into amendments to the 2017 Loan Agreement (the “2018 Amendments”) pursuant to which the Company, subject to certain conditions, was eligible to borrow a third term loan of $20.0 million during the period from April 2, 2018 to December 31, 2018. Pursuant to the 2018 Amendments, since the third term loan became available and the Company did not draw upon the third term loan, a fee of 1% was applied to the difference between $20.0 million and the amount drawn, or $0.2 million . Term loans under the amended 2017 Loan Agreement bore interest at a floating rate equal to an index rate plus 7.73% , where the index rate was the greater of 0.77% or the 30 -day U.S. Dollar London Interbank Offered Rate (“LIBOR”) as reported in The Wall Street Journal , with the floating rate resetting monthly subject to a floor of 8.5% . The Company could make monthly interest-only payments until May 1, 2019 (or, subject to certain conditions, May 1, 2020), and thereafter monthly payments of principal and interest were required to fully amortize the borrowed amount by a final maturity date of March 1, 2022 . A fee of 5% of each funded draw was due at the earlier of prepayment or loan maturity, a facility fee of 0.5% was due upon funding for each draw, and a prepayment fee of between 1% and 3% of the outstanding balance applied in the event of a prepayment. Concurrent with each term loan, the Company granted to the lender a warrant to acquire shares of the Company’s common stock equal to the quotient of 3% of the funded amount divided by a per share exercise price equal to the lower of the average closing price for the previous ten days of trading (calculated on the day prior to funding) or the closing price on the day prior to funding. In connection with the initial term loan, in 2017, the Company issued the lender warrants to purchase 116,845 shares of common stock at an exercise price of $10.27 per share. The Company classified these warrants as equity with a fair value of $0.7 million . In connection with the second term loan, in 2018, the Company issued the lender warrants to purchase 85,482 shares of common stock at an exercise price of $7.02 per share. The Company classified these warrants as equity with a fair value of $0.4 million . All warrants issued pursuant to the amended 2017 Loan Agreement have a term of ten years from the date of issuance and include a cashless exercise provision. In November 2018, the Company entered into a Note Purchase Agreement (the "2018 Note Purchase Agreement") pursuant to which the Company was eligible to borrow an aggregate principal amount up to $200.0 million over a seven year maturity term which included an initial borrowing of $75.0 million in November 2018. The Company received net proceeds of $10.3 million after terminating and repaying the balance of its obligations of approximately $64.7 million under the 2017 Loan Agreement and associated amendments with its previous lender. The Company incurred $5.3 million of debt extinguishment costs upon terminating its previous debt facility which the Company recorded as other income (expense), net in its consolidated statements of operations during the year ended December 31, 2018. At December 31, 2018 , obligations under the 2018 Note Purchase Agreement were $75.0 million which are required to be repaid to the lender in a balloon payment no later than 2025. If the Company repays prior to the three year anniversary following the initial borrowing, the amount due will be: 117.5% of the principal amount if payment is made within 12 months after the borrowing; 132.5% of the principal amount if payment is made between 12 and 24 months after the borrowing; and 145.0% of the principal amount if payment is made between 24 and 36 months after the borrowing. The outstanding principal amount under the 2018 Note Purchase Agreement bears interest at a rate of 8.75% annually. In addition, beginning on January 1, 2020 and continuing until repayment or maturity of any outstanding principal, the Company will make quarterly payments of 0.5% of the Company's annual net revenues subject to a maximum annual amount of such payments of $1.6 million which will be recognized as interest expense. Through the fixed interest charges and the quarterly revenue payments, the Company is required to pay total amounts to generate an 11% internal rate of return to the lender on any outstanding principal balances due in a lump-sum upon the repayment or maturity of any outstanding principal. During the year ended December 31, 2018 , the 2018 Note Purchase Agreement bore interest at an average interest rate of 10.6% . The 2018 Note Purchase Agreement contains quarterly covenants to achieve certain revenue levels as well as additional covenants, including limits on the Company’s ability to dispose of assets, undergo a change of control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of its capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The Company’s obligations under the 2018 Note Purchase Agreement are secured by a security interest on substantially all of its and certain of its subsidiaries’ assets. In connection with the 2018 Note Purchase Agreement, in November 2018, the Company entered into a Securities Purchase Agreement with the lender pursuant to which the Company issued 373,524 shares of its common stock at a price of $13.39 per share for an aggregate amount of $5.0 million . The share price paid by the lender was calculated based on the 15-day average closing share price prior to the issuance. The relative fair value method was used to allocate the proceeds between the common stock issued and the note proceeds; the fair value of the common stock issued to the lender was determined to be $5.4 million . Debt discounts, including debt issuance costs, related to the 2018 Note Purchase Agreement of $0.7 million were recorded as a direct deduction from the debt liability and are being amortized to interest expense over the term of the 2018 Note Purchase Agreement. Future estimated payments under the 2018 Note Purchase Agreement as of December 31, 2018 are as follows (in thousands): Amounts 2019 $ 6,654 2020 8,297 2021 8,279 2022 8,279 2023 8,279 Thereafter 89,998 Total remaining payments 129,786 Less: amount representing debt discount (721 ) Less: amount representing interest (54,588 ) Total non-current debt obligation $ 74,477 Interest expense related to the Company's debt financings was $6.7 million , $3.5 million and $0.3 million for the years ended December 31, 2018 , 2017 and 2016 , respectively. Capital leases The Company has entered into various capital lease agreements to obtain laboratory equipment. The terms of the Company's capital leases are typically three years and are secured by the underlying equipment. The portion of the future payments designated as principal repayment was classified as a capital lease obligation on the consolidated balance sheets. Future payments under capital leases at December 31, 2018 were as follows (in thousands): Amounts 2019 $ 2,087 2020 1,392 2021 21 Total capital lease obligations 3,500 Less: amount representing interest (188 ) Present value of net minimum capital lease payments 3,312 Less: current portion (1,937 ) Total non-current capital lease obligations $ 1,375 Interest expense related to capital leases was $0.3 million , $0.2 million and $0.1 million for the years ended December 31, 2018 , 2017 and 2016 , respectively. Property and equipment under capital leases was $7.1 million and $11.4 million as of December 31, 2018 and 2017 , respectively. Accumulated depreciation, collectively, on these assets was $2.0 million and $3.0 million at December 31, 2018 and 2017 , respectively. Guarantees and indemnifications As permitted under Delaware law and in accordance with the Company’s bylaws, the Company indemnifies its directors and officers for certain events or occurrences while the officer or director is or was serving in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company maintains director and officer liability insurance. This insurance allows the transfer of the risk associated with the Company’s exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company did not record any liabilities associated with these indemnification agreements at December 31, 2018 or December 31, 2017 . Other commitments In the normal course of business, the Company enters into various purchase commitments primarily related to service agreements, laboratory supplies, and a co-development agreement. At December 31, 2018 , the Company’s total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year were as follows (in thousands): Amount 2019 $ 3,040 2020 3,040 2021 1,440 Total $ 7,520 In addition, in September 2018, the Company entered into a co-development agreement with a privately held genetics testing company. The co-development agreement grants the Company the right of first refusal to enter into an agreement for an acquisition of the entity in return for total fees of $3.0 million over the term of the 12-month agreement, of which $1.0 million has been paid by the Company as of December 31, 2018 . The unpaid fees of $2.0 million were paid in January 2019, and as of December 31, 2018 , were recorded as an accrued liability in the Company’s consolidated balance sheets. Contingencies The Company was not a party to any material legal proceedings at December 31, 2018

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	Stockholders’ Equity Common stock As of December 31, 2018 and 2017 , the Company had reserved shares of common stock, on an as‑if converted basis, for issuance as follows (in thousands): As of December 31, 2018 2017 Options issued and outstanding 3,855 4,115 RSU awards issued and outstanding 4,031 2,387 Shares available for grant under stock option plans 118 2,397 Shares reserved for issuance under the 2015 Employee Stock Purchase Plan 278 308 Common stock underlying warrants 611 1,962 Common stock issuable upon conversion of preferred stock 3,459 3,459 Common stock underlying stock payable liabilities 132 689 Common stock payable as contingent consideration 452 551 Total 12,936 15,868 Private placement In August 2017, in a private placement to certain accredited investors, the Company issued 5.2 million shares of its common stock at a price of $8.50 per share, and 3.5 million shares of its Series A convertible preferred stock at a price of $8.50 per share, for gross proceeds of approximately $73.5 million and net proceeds of $68.9 million . The Series A preferred stock is a non-voting common stock equivalent and conversion of the Series A preferred stock is prohibited if the holder exceeds a specified threshold of voting security ownership. The Series A preferred stock is convertible into common stock on a one-for-one basis , subject to adjustment for events such as stock splits, combinations and the like. The Series A Preferred Stock has the right to receive dividends first or simultaneously with payment of dividends on common stock, in an amount equal to the product of (i) the dividend payable on each share of common stock and (ii) the number of shares of common stock issuable upon conversion of a share of Series A Preferred Stock. The Series A Preferred Stock has no voting rights except as required by law, as modified by the Company’s Amended and Restated Certificate of Incorporation. In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock is entitled to receive $0.001 per share prior to the payment of any amount to any holders of capital stock of the Company ranking junior to the Series A Preferred Stock and thereafter shall participate pari passu with the holders of the Company’s common stock (on an as-if-converted-to-common-stock basis). During January and February 2019, 1.1 million shares of Series A convertible preferred stock were converted to 1.1 million shares of common stock. Public offering In April 2018, the Company issued, in an underwritten public offering, an aggregate of 12.8 million shares of its common stock at a price of $4.50 per share, for gross proceeds of $57.5 million and net proceeds of $53.5 million . 2018 Sales Agreement In August 2018, the Company entered into a Common Stock Sales Agreement (the “2018 Sales Agreement”) with Cowen and Company, LLC (“Cowen”), under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through Cowen as its sales agent, in an aggregate amount not to exceed $75.0 million . Cowen may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The New York Stock Exchange, and also may sell the shares in privately negotiated transactions, subject to the Company’s prior approval. The Company is obligated to pay Cowen a commission equal to 3% of the gross proceeds of the sales price of all shares sold through it as sales agent under the 2018 Sales Agreement. During the year ended December 31, 2018, the Company issued a total of 4.3 million shares of common stock under the 2018 Sales Agreement for aggregate gross proceeds of $61.1 million and net proceeds of $58.9 million . Common stock warrants As of December 31, 2018 , the Company had outstanding warrants to purchase common stock as follows: Warrant Issuance Date Expiration Date Exercise Price Per Share Number of Shares of Common Stock Underlying Warrants Warrants issued in exchange for CombiMatrix Series F warrants November 2017 March 2021 $ 5.95 408,548 Warrants issued to lender under 2017 Loan Agreement March 2017 March 2027 $ 10.27 116,845 Warrants issued to lender under 2017 Loan Agreement - 2018 Amendments March 2018 March 2028 $ 7.02 85,482 610,875 The exercise price of warrants issued in exchange for CombiMatrix Series F warrants was determined pursuant to the terms of the Merger Agreement (See Note 4, "Business Combinations"). The CombiMatrix Series D warrants expired during the year ended December 31, 2018. The exercise price of the warrants issued to the lender under the 2017 Loan Agreement was the closing price of the Company’s common stock on the date of the agreements. During the year ended December 31, 2018 , the Company received $6.5 million from exercises 1.0 million

Stock incentive plans

Stock incentive plans	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock incentive plans	Stock incentive plans Stock incentive plans In 2010, the Company adopted the 2010 Incentive Plan (the “2010 Plan”). The 2010 Plan provides for the granting of stock-based awards to employees, directors and consultants under terms and provisions established by the Board of Directors. Under the terms of the 2010 Plan, options may be granted at an exercise price not less than fair market value. For employees holding more than 10% of the voting rights of all classes of stock, the exercise prices for incentive and nonstatutory stock options must be at least 110% of fair market of the common stock on the grant date, as determined by the Board of Directors. The terms of options granted under the 2010 Plan may not exceed ten years . In January 2015, the Company adopted the 2015 Stock Incentive Plan (the “2015 Plan”), which became effective upon the closing of the Company’s initial public offering (“IPO”). Shares outstanding under the 2010 Plan were transferred to the 2015 Plan upon effectiveness of the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 through January 1, 2025. In addition, shares subject to awards under the 2010 Plan that are forfeited or terminated will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, stock units, stock appreciation rights and other forms of equity compensation, all of which may be granted to employees, including officers, non-employee directors and consultants. Additionally, the 2015 Plan provides for the grant of cash-based awards. Options granted generally vest over a period of four years . Typically, the vesting schedule for options granted to newly hired employees provides that 1/4 of the award vests upon the first anniversary of the employee’s date of hire, with the remainder of the award vesting monthly thereafter at a rate of 1/48 of the total shares subject to the option. All other options typically vest in equal monthly installments over the four -year vesting schedule. RSUs generally vest over a period of three years . Typically, the vesting schedule for RSUs provides that one third of the award vests upon each anniversary of the grant date. In February 2016, the Company granted PRSUs under the 2015 Plan, which PRSUs could be earned based on the achievement of specified performance conditions measured over a period of approximately 12 months . In February 2017, upon the Audit Committee’s determination of the level of achievement, 352,045 fully vested stock units were awarded to holders of PRSUs. The Company has not granted any PRSUs since 2016. Based on its evaluations of the probability of achieving performance conditions, the Company recorded stock-based compensation expense of nil , $0.4 million , and $1.9 million for the years ended December 31, 2018 , 2017 , and 2016 , respectively, related to the PRSUs. Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share amounts and years): Shares Available For Grant Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Balance at December 31, 2017 2,397 4,115 $ 8.51 7.6 $ 5,128 Additional shares reserved 754 — Options granted (260 ) 260 $ 8.50 Options cancelled 169 (169 ) $ 9.35 Options exercised — (351 ) $ 7.73 RSUs granted (3,282 ) — RSUs cancelled 340 — Balance at December 31, 2018 118 3,855 $ 8.54 6.8 $ 9,927 Options exercisable at December 31, 2018 2,737 $ 8.27 6.4 $ 7,787 Options vested and expected to vest at December 31, 2018 3,710 $ 8.52 6.8 $ 9,626 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock for stock options that were in-the-money. The weighted-average fair value of options to purchase common stock granted was $4.87 , $5.82 and $6.18 in the years ended December 31, 2018 , 2017 and 2016 , respectively. The weighted-average fair value of RSUs granted was $7.46 , $10.03 and $9.80 in the years ended December 31, 2018 , 2017 and 2016 , respectively. No PRSUs were granted in the years ended December 31, 2018 or 2017 and the weighted average fair value of PRSUs granted in the year ended December 31, 2016 was $6.50 . The total grant-date fair value of options to purchase common stock vested was $5.9 million , $6.9 million and $5.6 million in the year ended December 31, 2018 , 2017 , and 2016 , respectively. The intrinsic value of options to purchase common stock exercised was $1.7 million , $2.1 million and $1.4 million in the years ended December 31, 2018 , 2017 and 2016 , respectively. The following table summarizes RSU activity for the year ended December 31, 2018 (in thousands, except per share data: Number of Shares Weighted-Average Grant Date Fair Value Balance at December 31, 2017 2,387 $ 9.91 RSUs granted 3,282 $ 7.46 RSUs vested (1,298 ) $ 8.84 RSUs cancelled (340 ) $ 8.84 Balance at December 31, 2018 4,031 $ 8.35 2015 employee stock purchase plan In January 2015, the Company adopted the 2015 Employee Stock Purchase Plan (the “ESPP”), which became effective upon the closing of the IPO. Employees participating in the ESPP may purchase common stock at 85% of the lesser of the fair market value of common stock on the purchase date or last trading day preceding the offering date. At December 31, 2018 , cash received from payroll deductions pursuant to the ESPP was $0.6 million . The ESPP provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 and continuing through January 1, 2025. At December 31, 2018 , a total of 277,577 shares of common stock are reserved for issuance under the ESPP. Stock-based compensation The Company uses the grant date fair value of its common stock to value both employee and non-employee options when granted. The Company revalues non-employee options each reporting period using the fair market value of the Company’s common stock as of the last day of each reporting period. In determining the fair value of stock options and ESPP purchases, the Company uses the Black-Scholes option-pricing model and, for stock options, the assumptions discussed below. Each of these inputs is subjective and its determination generally requires significant judgment. The fair value of RSU and PRSU awards is based on the grant date share price. Compensation cost is recognized as expense on a straight-line basis over the vesting period for options and RSUs and on an accelerated basis for PRSUs. In 2016, the Company modified certain stock options and RSU awards. The terms of the stock option modifications included acceleration of vesting and extensions of post-termination exercise periods. The terms of the RSU award modifications included acceleration of vesting. A total of 14 employees were affected by the stock option and RSU modifications and the total incremental compensation cost relating to these modifications was $0.3 million . Expected term —The expected term represents the period that the Company’s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term). Expected volatility —Because the Company was privately held until its initial public offering in February 2015 and did not have any trading history for its common stock, the Company estimates expected volatility using its own stock price volatility when available as well as the average volatility for comparable publicly traded life sciences companies, including molecular diagnostics companies, over a period equal to the expected term of stock option grants and RSUs. When selecting comparable publicly-traded biopharmaceutical companies, including molecular diagnostics companies, the Company selected companies with comparable characteristics, including enterprise value, risk profiles, position within the industry and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computed historical volatility data using daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The Company estimates expected volatility for ESPP purchases using its own stock price volatility over the expected six -month term ESPP purchase periods. Risk-free interest rate —The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. Dividend yield —The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. The fair value of share-based payments for stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model based on the following assumptions: Year Ended December 31, 2018 2017 2016 Expected term (in years) 6.00 6.03 6.03 Expected volatility 59.58% 72.64% 71.42% Risk-free interest rate 2.80% 2.01% 1.37% Stock-based compensation related to stock options granted to non-employees is recognized as the stock options vest. The fair value of the stock options granted is calculated at each reporting date using the Black-Scholes option-pricing model based on the following assumptions: Year Ended December 31, 2018 2017 2016 Expected term (in years) — 8.41 – 8.83 6.25 – 10.00 Expected volatility — 69.9 – 78.70% 76.92% Risk-free interest rate — 1.83 – 2.04% 1.55 – 2.37% No stock options granted to non-employees vested during the year ended December 31, 2018. The fair value of shares purchased pursuant to the ESPP is estimated using the Black‑Scholes option pricing model. For the years ended December 31, 2018 , 2017 and 2016 , the weighted average grant date fair value per share for the ESPP was $3.26 , $2.51 and $2.66 , respectively and stock‑based compensation expense for the ESPP was $1.4 million , $1.1 million and $0.9 million , respectively. The fair value of the shares purchased pursuant to the ESPP was estimated using the following assumptions: Year Ended December 31, 2018 2017 2016 Expected term (in years) 0.5 0.5 0.5 Expected volatility 71.66% 52.50% 66.31% Risk-free interest rate 2.09% 1.23% 0.50% The following table summarizes stock-based compensation expense for the years ended December 31, 2018 , 2017 and 2016 , included in the consolidated statements of operations (in thousands): Year Ended December 31, 2018 2017 2016 Cost of revenue $ 2,960 $ 2,093 $ 1,353 Research and development 7,017 6,158 4,976 Selling and marketing 4,887 3,956 1,709 General and administrative 5,986 7,014 2,661 Total stock-based compensation expense $ 20,850 $ 19,221 $ 10,699 At December 31, 2018 , unrecognized compensation expense related to unvested stock options, net of estimated forfeitures, was $4.5 million , which the Company expects to recognize on a straight-line basis over a weighted-average period of 1.8 years . Unrecognized compensation expense related to RSUs at December 31, 2018 , net of estimated forfeitures, was $22.6 million , which the Company expects to recognize on a straight-line basis over a weighted-average period of 2.1 years . At December 31, 2018 , there was no unrecognized compensation expense related to PRSUs and no

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The Company recorded a benefit for income taxes in the years ended December 31, 2018 and 2017 . The Company did not record a provision or benefit for income taxes during the year ended December 31, 2016 . The components of net loss before taxes by U.S. and foreign jurisdictions are as follows (in thousands): Year Ended December 31, 2018 2017 2016 United States $ 132,194 $ 124,108 $ 99,793 Foreign (39 ) 1,128 463 Total $ 132,155 $ 125,236 $ 100,256 The components of the provision for income taxes are as follows (in thousands): Year Ended December 31, 2018 2017 2016 Current: Foreign 62 — — Total current benefit for income taxes 62 — — Deferred: Federal (2,862 ) (1,704 ) — State — (152 ) — Total deferred benefit for income taxes (2,862 ) (1,856 ) — Total income tax benefit $ (2,800 ) $ (1,856 ) $ — The following table presents a reconciliation of the tax expense computed at the statutory federal rate and the Company’s tax expense for the periods presented: Year Ended December 31, 2018 2017 2016 U.S. federal taxes at statutory rate 21.0 % 34.0 % 34.0 % State taxes (net of federal benefit) 5.2 % 3.3 % 1.4 % Stock-based compensation (0.7 )% (1.1 )% (1.7 )% Research and development credits 2.7 % — % — % Non-deductible expenses (0.6 )% — % 0.2 % Foreign tax differential — % (0.3 )% (0.2 )% Other — % — % 1.1 % Change in valuation allowance (25.5 )% (34.4 )% (34.8 )% Change in deferred—Tax Reform — % (39.0 )% — % Change in valuation allowance—Tax Reform — % 39.0 % — % Total 2.1 % 1.5 % — % The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands): As of December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 76,972 $ 70,825 Tax credits 15 15 Revenue recognition differences 47,650 29,819 Accruals and other 7,262 5,544 Gross deferred tax assets 131,899 106,203 Valuation allowance (121,954 ) (95,687 ) Total deferred tax assets 9,945 10,516 Deferred tax liabilities: Property and equipment (9,945 ) (10,516 ) Total deferred tax liabilities (9,945 ) (10,516 ) Net deferred tax assets $ — $ — On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes included among other items, a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% . Although the Tax Act was generally effective January 1, 2018, GAAP required recognition of the tax effects of new legislation during the reporting period that includes the enactment date, which was December 22, 2017. As a result of the lower corporate tax rate enacted as part of the Tax Act, during 2017, the Company recorded a provisional estimate to reduce deferred tax assets by $ 48.8 million offset by a corresponding reduction in the valuation allowance resulting in no net impact to the Company's income tax benefit or expense. On December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. In accordance with SAB 118, during 2017, the Company recorded a provisional estimate which resulted in a $48.8 million reduction in deferred tax assets and in the fourth quarter of 2018, the Company completed its analysis of the impact of the Tax Act and determined that no material adjustments were required to the provisional amounts previously recorded. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets. The Company's valuation allowance increased by $26.3 million , $2.0 million , and $33.4 million during the years ended December 31, 2018 , 2017 , and 2016 , respectively. As of December 31, 2018 , the Company had net operating loss carryforwards of approximately $318.7 million and $134.3 million available to reduce future taxable income, if any, for Federal and state income tax purposes, respectively. Of the $318.7 million , $277.3 million will begin to expire in 2030 while $41.4 million have no expiration date. The state net operating loss carryforwards will begin to expire in 2030. As of December 31, 2018 , the Company had research and development credit carryforwards of approximately $9.0 million and $7.4 million available to reduce its future tax liability, if any, for Federal and state income tax purposes, respectively. The Federal credit carryforwards begin to expire in 2030. California credit carryforwards have no expiration date. Internal Revenue Code ("IRC") section 382 places a limitation (the “Section 382 limitation” or “annual limitation”) on the amount of taxable income that can be offset by net operating loss carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. Similar provisions exist for states. In addition, and as a result of the acquisitions of Good Start Genetics and CombiMatrix in 2017, tax loss carryforwards from acquired entities are also subject to the Section 382 limitation due to the change in control in the acquired entities in the current year. The Company performed a section 382 analysis for Good Start Genetics and CombiMatrix and concluded that a substantial portion of the acquired operating loss and credit carryovers would expire unused as a result of annual limitations under IRC sections 382 and 383 in 2017. As a result, the federal and state operating loss and credit carryforwards acquired in connection with the Good Start Genetics and CombiMatrix acquisitions were reduced by the amount of tax attributes estimated to expire during their respective carryforward periods. In addition, as a result of equity issued in connection with its 2017 acquisitions, the Company also performed a section 382 analysis with respect to its legacy operating loss and credit carryforwards. The Company concluded while an ownership change occurred in 2017 as defined under IRC section 382, none of the Company’s legacy carryforwards would expire unused solely as a result of annual limitations imposed on the use of the carryforwards under IRC sections 382 and 383. As of December 31, 2018 , the Company had unrecognized tax benefits of $16.4 million , which primarily relates to research and development credits, none of which would currently affect the Company’s effective tax rate if recognized due to the Company’s deferred tax assets being fully offset by a valuation allowance. Unrecognized tax benefits are not expected to change in the next 12 months. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year ended December 31, 2018 2017 2016 Unrecognized tax benefits, beginning of period $ 10,561 $ 7,791 $ 11,429 Gross increases—current period tax positions 5,686 2,552 782 Gross increases (decreases)—prior period tax positions 128 218 (4,420 ) Unrecognized tax benefits, end of period $ 16,375 $ 10,561 $ 7,791 The Company’s policy is to include penalties and interest expense related to income taxes as a component of tax expense. The Company has not accrued interest and penalties related to the unrecognized tax benefits reflected in the financial statements for the years ended December 31, 2018 , 2017 and 2016 . The Company’s major tax jurisdictions are the United States and California. All of the Company’s tax years will remain open for examination by the Federal and state tax authorities for three and four years

Net loss per common share

Net loss per common share	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Net loss per common share	Net loss per share The following table presents the calculation of basic and diluted net loss per share for the years ended December 31, 2018 , 2017 and 2016 (in thousands, except per share data): Year ended December 31, 2018 2017 2016 Net loss $ (129,355 ) $ (123,380 ) $ (100,256 ) Shares used in computing net loss per share, basic and diluted 66,747 46,512 33,176 Net loss per share, basic and diluted $ (1.94 ) $ (2.65 ) $ (3.02 ) The following common stock equivalents have been excluded from diluted net loss per share for the years ended December 31, 2018 , 2017 and 2016 because their inclusion would be anti-dilutive (in thousands): Year Ended December 31, 2018 2017 2016 Shares of common stock subject to outstanding options 3,855 4,115 4,491 Shares of common stock subject to outstanding warrants 611 1,962 — Shares of common stock subject to outstanding RSUs 4,031 2,387 892 Shares of common stock subject to outstanding PRSUs — — 530 Shares of common stock pursuant to ESPP 63 59 55 Shares of common stock underlying Series A convertible preferred stock 3,459 3,459 — Total shares of common stock equivalents 12,019 11,982 5,968

Geographic information

Geographic information	12 Months Ended
	Dec. 31, 2018
Segments, Geographical Areas [Abstract]
Geographic information	Geographic information Revenue by country is determined based on the billing address of the customer and is summarized as follows (in thousands): Year Ended December 31, 2018 2017 2016 United States $ 138,239 $ 62,446 $ 20,758 Canada 4,206 3,226 2,526 Rest of world 5,254 2,549 1,764 Total revenue $ 147,699 $ 68,221 $ 25,048 As of December 31, 2018 and 2017

Selected quarterly data (unaudi

Selected quarterly data (unaudited)	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Selected quarterly data (unaudited)	Selected quarterly data (unaudited) The following table summarizes the Company's quarterly financial information for 2018 and 2017 (in thousands, except per share amounts): Three Months Ended March 31, 2018 June 30, 2018 September 30, 2018 December 31, 2018 Revenue $ 27,671 $ 37,306 $ 37,366 $ 45,356 Cost of revenue $ 18,076 $ 20,447 $ 20,441 $ 21,141 Loss from operations $ (36,475 ) $ (30,068 ) $ (30,110 ) $ (25,904 ) Net loss (2) $ (36,120 ) $ (31,671 ) $ (31,723 ) $ (29,841 ) Net loss per share, basic and diluted (1) $ (0.66 ) $ (0.47 ) $ (0.45 ) $ (0.40 ) Three Months Ended March 31, 2017 June 30, 2017 September 30, 2017 December 31, 2017 Revenue $ 10,338 $ 14,336 $ 18,148 $ 25,399 Cost of revenue $ 9,329 $ 10,490 $ 13,274 $ 17,049 Loss from operations $ (27,337 ) $ (28,075 ) $ (30,976 ) $ (34,891 ) Net loss (2) $ (26,928 ) $ (28,557 ) $ (27,402 ) $ (40,493 ) Net loss per share, basic and diluted (1) $ (0.64 ) $ (0.66 ) $ (0.57 ) $ (0.78 ) ___________________________________________________________________ (1) Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of quarterly net loss per share information may not equal annual net loss per share. (2) Includes $5.3 million

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidationThe consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company bases these estimates on historical and anticipated results, trends and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates and assumptions. Significant estimates and assumptions made by management include the determination of: • revenue recognition (See Note 3, “Revenue, accounts receivable and deferred revenue” for further information); • the fair value of assets acquired and liabilities assumed for business combinations; • the fair value of goodwill and intangible assets; • the recoverability of long-lived assets; • stock-based compensation expense and the fair value of awards issued; and •
Concentrations of credit risk and other risks and uncertainties	Concentrations of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash and cash equivalents are held by financial institutions in the United States. Such deposits may exceed federally insured limits. Significant customers are those that represent 10%
Cash, cash equivalents, and restricted cash	Cash, cash equivalents, and restricted cash The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and U.S. government agency securities.
Marketable securities	Marketable securitiesAll marketable securities have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. Short-term marketable securities have maturities less than 365 days at the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest and other income (expense), net.
Accounts receivable	Accounts receivableThe Company receives payment for its tests from partners, patients, institutional customers and third-party payers.
Inventory	InventoryThe Company maintains test reagents and other consumables primarily used in sample collection kits which are valued at the lower of cost or market value. Cost is determined using actual costs on a first-in, first-out basis.
Business combinations	Business combinations The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under Financial Accounting Standards Board (“FASB") Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity , the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company remeasures this liability each reporting period and records changes in the fair value as a component of operating expenses.
Intangible assets	Intangible assets Amortizable intangible assets include trade names, non-compete agreements, developed technology and customer relationships acquired as part of business combinations. Customer relationships are amortized on an accelerated basis, utilizing free cash flows, over periods ranging from five to 11 years . All other intangible assets subject to amortization are amortized using the straight-line method over their estimated useful lives ranging from two to 15 years . All intangible assets subject to amortization are reviewed for impairment in accordance with ASC 360,
Goodwill	Goodwill In accordance with ASC 350, Intangibles-Goodwill and Other
Leases	LeasesThe Company rents its facilities under operating lease agreements and recognizes related rent expense on a straight-line basis over the term of the applicable lease agreement. Some of the lease agreements contain rent holidays, scheduled rent increases, lease incentives, and renewal options. Rent holidays and scheduled rent increases are included in the determination of rent expense to be recorded over the lease term. Lease incentives are recognized as a reduction of rent expense on a straight-line basis over the term of the lease. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The Company recognizes rent expense beginning on the date it obtains the legal right to use and control the leased space.
Property and equipment, net	Property and equipment, net Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight‑line method over the estimated useful lives of the assets, generally between three and seven years . Leasehold improvements are amortized using the straight‑line method over the shorter of the estimated useful life of the asset or the term of the lease. Amortization expense of assets acquired through capital leases is included in depreciation and amortization expense in the consolidated statements of operations. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized. The estimated useful lives of property and equipment are as follows: Furniture and fixtures 7 years Automobiles 7 years Laboratory equipment 5 years Computer equipment 3 years Software 3 years Leasehold improvements Shorter of lease term or estimated useful life
Long-lived assets	Long‑lived assetsThe Company reviews long‑lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows or other appropriate measures of fair value.
Variable interest entity	Variable interest entityThe Company had a variable interest in a variable interest entity (“VIE”) through an investment in convertible notes issued by the VIE. The convertible notes do not provide the Company with voting rights in the VIE or with power to direct the activities of the VIE which most significantly affect its economic performance. The Company is not the VIE’s primary beneficiary and it does not consolidate the VIE.
Fair value of financial instruments	Fair value of financial instrumentsThe Company’s financial instruments consist principally of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities, capital leases and debt. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to the Company, the carrying value of capital leases and debt approximate their fair values.
Revenue recognition and cost of revenue	Revenue recognition The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers. Test revenue is generated primarily from the sale of tests that provide analysis and associated interpretation of the sequencing of parts of the genome. Other revenue consists primarily of revenue from genome network subscription services which is recognized on a straight-line basis over the subscription term, and revenue from collaboration agreements. Cost of revenue
Income taxes	Income taxesThe Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Stock-based compensation	Stock-based compensation The Company measures its stock-based payment awards made to employees and directors based on the estimated fair values of the awards and recognizes the compensation expense over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards and employee stock purchase plan (“ESPP”) purchases. The fair value of restricted stock unit (“RSU”) awards with time-based vesting terms is based on the grant date share price. The Company grants performance-based restricted stock unit (“PRSU”) awards to certain employees which vest upon the achievement of certain performance conditions, subject to the employees’ continued service relationship with the Company. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment. The Company recognizes such compensation expense on an accelerated vesting method. Stock-based compensation expense for awards without a performance condition is recognized using the straight-line method. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company’s stock-based compensation is reduced for estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company accounts for compensation expense related to stock options granted to non-employees based on fair values estimated using the Black-Scholes option-pricing model. Stock options granted to non-employees are re-measured at each reporting date until the award is vested.
Advertising	AdvertisingAdvertising expenses are expensed as incurred.
Comprehensive loss	Comprehensive lossComprehensive loss is composed of two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity, but are excluded from net loss. The Company’s other comprehensive income (loss) consists of unrealized gains or losses on investments in available-for-sale securities.
Net loss per share	Net loss per shareBasic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities, consisting of preferred stock, options to purchase common stock, common stock warrants, RSUs and PRSUs, are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per share because their effect would be antidilutive for all periods presented.
Recent accounting pronouncements	Recent accounting pronouncements The Company evaluates all Accounting Standards Updates (“ASUs”) issued by the FASB for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s consolidated financial statements. Recently issued accounting pronouncements not yet adopted In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 , which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Accounting Standards Codification ("ASC") 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January 1, 2020. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) , which replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019, with early adoption permitted for the fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and in July 2018 issued ASU 2018-10 , Codification Improvements to Topic 842, Leases and ASU 2018-11 , Leases (Topic 842): Targeted Improvements (the foregoing ASUs collectively referred to as “Topic 842”). Under the new guidance, lessees are required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) at the commencement date and also requires expanded disclosures about leasing arrangements. Topic 842 is effective for annual and interim periods beginning on or after December 15, 2018 and early adoption is permitted. Entities may initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is evaluating the final effect that Topic 842 and related standards will have on its consolidated financial statements, related disclosures and ongoing financial reporting, but expects implementation of Topic 842 to result in the recognition of material right of use assets and corresponding lease liabilities in its consolidated balance sheets as of the implementation of Topic 842 on January 1, 2019, principally relating to facilities leases. The Company does not have any material embedded leases and the implementation of Topic 842 is primarily focused on the treatment of the Company's previously identified leases. As of December 31, 2018, the Company's total future undiscounted capital lease payments were $3.5 million and future undiscounted non-cancelable minimum operating lease payments, net of subleases were $78.4 million Recently adopted accounting pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), designed to enable users of financial statements to better understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. On January 1, 2018, the Company adopted the provisions of Topic 606 using the modified retrospective method. From adoption to date, the Company has recognized all its revenue from contracts with customers within the scope of Topic 606. In connection with the adoption, the Company recognized the cumulative effect of initially applying this standard as an adjustment to retained earnings on the date of adoption. Comparative information prior to the date of adoption has not been restated and continues to be reported under the accounting standards in effect for those periods. In connection with the adoption of Topic 606, the Company amended its revenue recognition policy to provide for the recognition of certain variable consideration related to diagnostic tests that was previously deferred pending cash collection. Under Topic 606, the Company records variable consideration based on an estimate of the consideration to which it will be entitled. The Company recognizes revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers. Diagnostic tests The majority of the Company’s revenue is generated from genetic testing services that provide analysis and associated interpretation of the sequencing of parts of the genome. Test orders are placed under signed requisitions, and the Company often enters into contracts with institutions (e.g., hospitals and clinics) and insurance companies that include pricing provisions under which such tests are billed. Billing terms are generally net thirty days. While the transaction price of diagnostic tests is originally established either via contract or pursuant to the Company’s standard list price, the Company often provides concessions for tests billed to insurance carriers, and therefore the transaction price for patient insurance-billed tests is considered to be variable and revenue is recognized based on an estimate of the consideration to which the Company will be entitled at an amount for which it is probable that a reversal of cumulative consideration will not occur. Making these estimates requires significant judgments based upon such factors as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. These judgments are reviewed quarterly and revenue recognized is updated, as necessary, until the Company’s obligations are fully settled. In connection with some diagnostic test orders, the Company offers limited re-requisition rights (“Re-Requisition Rights”) that are considered distinct at contract inception, and therefore certain diagnostic test orders contain two performance obligations, the performance of the original test and the Re-Requisition Rights. When Re-Requisition Rights are granted, the Company allocates the transaction price to each performance obligation based on the relative estimated standalone selling prices. In order to comply with loss contract rules, the allocations are adjusted, if necessary, to ensure the amount deferred for Re-Requisition Rights is no less than the estimated cost of fulfilling the Company’s related obligations. The Company looks to transfer of control in assessing timing of recognition of revenue in connection with each performance obligation. In general, revenue in connection with diagnostic tests is recognized upon delivery of the underlying clinical report or when the report is made available on the Company’s web portal. Outstanding performance obligations pertaining to orders received but for which the underlying report has not been issued are generally satisfied within a thirty-day period. Revenue in connection with Re-Requisition Rights is recognized as the rights are exercised or expire unexercised, which is generally within ninety days of initial deferral. Other contracts The Company also enters into collaboration and genome network contracts. Collaboration agreements provide customers with diagnostic testing and related data aggregation reporting services that are provided over the contract term. Collaboration revenue is recognized as the testing and reporting services are delivered to the customer. Genome network offerings consist of subscription services related to a proprietary software platform designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis and treatment of hereditary disease. Such services are recognized on a straight-line basis over the subscription periods.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule significant customer, revenue as a percentage	For the significant customer, revenue as a percentage of total revenue were as follows: December 31, Customers 2018 2017 2016 Medicare 22 % 13 % 11 %
Schedule of restrictions on cash and cash equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands): December 31, 2018 December 31, 2017 Cash and cash equivalents $ 112,158 $ 12,053 Restricted cash 6,006 5,406 Total cash, cash equivalents and restricted cash $ 118,164 $ 17,459
Schedule of cash, cash equivalents and restricted cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands): December 31, 2018 December 31, 2017 Cash and cash equivalents $ 112,158 $ 12,053 Restricted cash 6,006 5,406 Total cash, cash equivalents and restricted cash $ 118,164 $ 17,459
Schedule of useful lives of property and equipment	The estimated useful lives of property and equipment are as follows: Furniture and fixtures 7 years Automobiles 7 years Laboratory equipment 5 years Computer equipment 3 years Software 3 years Leasehold improvements Shorter of lease term or estimated useful life

Revenue, accounts receivable _2

Revenue, accounts receivable and deferred revenue (Tables)	12 Months Ended
	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Schedule of impact of adoption of topic 606 on condensed consolidated statement of operations and balance sheet	The effect of the adoption of Topic 606 on financial statement line items in the Company’s consolidated statement of operations for the year ended December 31, 2018 , and the Company’s consolidated balance sheet as of December 31, 2018 was as follows (in thousands, except per share amounts): Year Ended December 31, 2018 Without Effect of Adoption of Adoption As Reported Topic 606 Higher/(Lower) Test revenue $ 144,560 $ 144,222 $ 338 Net loss $ (129,355 ) $ (129,693 ) $ 338 Net loss per share, basic and diluted $ (1.94 ) $ (1.94 ) $ — As of December 31, 2018 Without Effect of Adoption of Adoption As Reported Topic 606 Higher/(Lower) Accounts receivable $ 26,296 $ 14,150 $ 12,146 Accumulated deficit $ (516,712 ) $ (528,291 ) $ 11,579 Stockholders' equity $ 161,839 $ 150,260 $ 11,579
Schedule of disaggregated revenue by payer category	The following table includes the Company’s revenues as disaggregated by payer category (in thousands): Year Ended December 31, 2018 2017 (1) Test revenue: Institutions $ 34,618 $ 17,238 Patient - direct 13,589 5,638 Patient - insurance 96,353 42,293 Total test revenue 144,560 65,169 Other revenue 3,139 3,052 Total revenue $ 147,699 $ 68,221 ___________________________________________________________________ (1)

Business combinations (Tables)

Business combinations (Tables)	12 Months Ended
	Dec. 31, 2018
AltaVoice
Business Acquisition [Line Items]
Summary of fair values of assets acquired and liabilities assumed	The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands): Cash $ 54 Accounts receivable 274 Prepaid expense and other assets 52 Non-compete agreement 286 Developed technology 570 Customer relationships 3,389 Total identifiable assets acquired 4,625 Accounts payable (28 ) Deferred revenue (202 ) Accrued expenses (21 ) Deferred tax liability (1,422 ) Total liabilities assumed (1,673 ) Net identifiable assets acquired 2,952 Goodwill 9,432 Net assets acquired $ 12,384
Schedule of economic benefits of intangible assets expected to be realized	Acquisition-related intangibles included in the above table are finite-lived. Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of ten years . All other acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands): Gross Purchased Intangible Assets Estimated Useful Life (in Years) Non-compete agreement $ 286 5 Developed technology 570 6 Customer relationships 3,389 10 $ 4,245
Ommdom, Inc.
Business Acquisition [Line Items]
Summary of fair values of assets acquired and liabilities assumed	The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands): Cash $ 53 Accounts receivable 10 Prepaid expense and other assets 4 Trade name 13 Developed technology 2,335 Customer relationships 147 Total identifiable assets acquired 2,562 Accounts payable (16 ) Accrued expenses (17 ) Deferred tax liability (434 ) Total liabilities assumed (467 ) Net identifiable assets acquired 2,095 Goodwill 4,045 Net assets acquired $ 6,140
Schedule of economic benefits of intangible assets expected to be realized	Finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands): Gross Purchased Intangible Assets Estimated Useful Life (in Years) Trade name $ 13 5 Developed technology 2,335 5 Customer relationships 147 5 $ 2,495
Good Start Genetics
Business Acquisition [Line Items]
Summary of fair values of assets acquired and liabilities assumed	The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands): Cash and restricted cash $ 1,381 Accounts receivable 2,246 Prepaid expense and other assets 1,579 Property and equipment 1,320 Trade name 460 Developed technology 5,896 Customer relationships 7,830 Total identifiable assets acquired 20,712 Accounts payable (5,418 ) Accrued expenses (6,802 ) Notes payable (17,904 ) Convertible promissory notes payable (15,430 ) Other liabilities (222 ) Total liabilities assumed (45,776 ) Net identifiable assets acquired (25,064 ) Goodwill 25,064 Net assets acquired $ —
Schedule of economic benefits of intangible assets expected to be realized	Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of eight years . All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands): Gross Purchased Intangible Assets Estimated Useful Life (in Years) Trade name $ 460 3 Developed technology 5,896 5 Customer relationships 7,830 8 $ 14,186
CombiMatrix
Business Acquisition [Line Items]
Summary of fair values of assets acquired and liabilities assumed	The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition (in thousands): Cash and restricted cash $ 1,333 Accounts receivable 4,118 Prepaid expense and other assets 1,299 Property and equipment 437 Other assets - non current 30 Favorable leases 247 Trade name 103 Patent licensing agreement 496 Developed technology 3,162 Customer relationships 12,397 Total identifiable assets acquired 23,622 Accounts payable (276 ) Accrued expenses (3,925 ) Deferred tax liability (2,862 ) Other liabilities (180 ) Total liabilities assumed (7,243 ) Net identifiable assets acquired 16,379 Goodwill 11,554 Net assets acquired $ 27,933
Schedule of economic benefits of intangible assets expected to be realized	Customer relationships are being amortized on an accelerated basis, utilizing free cash flows, over a period of eleven years . All other finite-lived intangibles included in the above table are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows (in thousands): Gross Purchased Intangible Assets Estimated Useful Life (in Years) Favorable leases $ 247 2 Trade name 103 1 Patent licensing agreement 496 15 Developed technology 3,162 4 Customer relationships 12,397 11 $ 16,405

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of goodwill	Details of the Company’s goodwill for the year ended December 31, 2018 are as follows (in thousands): AltaVoice Ommdom Good Start CombiMatrix Total Balance as of December 31, 2017 $ 9,432 $ 4,045 $ 24,406 $ 8,692 $ 46,575 Goodwill adjustment — — 658 2,862 3,520 Balance as of December 31, 2018 $ 9,432 $ 4,045 $ 25,064 $ 11,554 $ 50,095
Schedule of finite-lived intangible assets	The following table presents details of the Company’s finite-lived intangible assets as of December 31, 2018 (in thousands): Cost Accumulated Amortization Net Weighted Average Useful Life (in Years) Weighted Average Estimated Remaining Useful Life (in Years) Customer relationships $ 23,763 $ (2,783 ) $ 20,980 10.0 8.6 Developed technology 11,963 (3,482 ) 8,481 4.8 3.4 Non-compete agreement 286 (114 ) 172 5.0 3.0 Trade name 576 (329 ) 247 2.7 1.4 Patent licensing agreement 496 (37 ) 459 15.0 13.9 Favorable leases 247 (117 ) 130 2.2 1.1 $ 37,331 $ (6,862 ) $ 30,469 8.2 6.8
Summary of estimated future amortization expense of intangible assets with finite lives	The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of December 31, 2018 (in thousands): Amount 2019 $ 5,250 2020 5,525 2021 5,829 2022 4,124 2023 3,111 Thereafter 6,630 Total estimated future amortization expense $ 30,469

Balance sheet components (Table

Balance sheet components (Tables)	12 Months Ended
	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Schedule of property and equipment, net	Property and equipment consisted of the following (in thousands): December 31, 2018 December 31, 2017 Leasehold improvements $ 13,034 $ 12,623 Laboratory equipment 22,149 17,705 Equipment under capital lease 7,129 11,446 Computer equipment 4,723 4,023 Software 2,594 2,520 Furniture and fixtures 784 569 Automobiles 20 20 Construction-in-progress 1,962 965 Total property and equipment, gross 52,395 49,871 Accumulated depreciation and amortization (24,509 ) (19,530 ) Total property and equipment, net $ 27,886 $ 30,341
Schedule of accrued liabilities	Accrued liabilities consisted of the following (in thousands): December 31, 2018 December 31, 2017 Accrued compensation and related expenses $ 7,917 $ 7,406 Deferred revenue 761 307 Liabilities associated with business combinations 6,460 9,497 Liability associated with co-development agreement 2,000 — Other 9,425 5,532 Total accrued liabilities $ 26,563 $ 22,742
Schedule of other long-term liabilities	Other long-term liabilities consisted of the following (in thousands): December 31, 2018 December 31, 2017 Lease incentive obligation, non-current $ 3,280 $ 3,831 Deferred rent, non-current 5,495 5,153 Liabilities associated with business combinations — 3,779 Other non-current liabilities 181 677 Total other long-term liabilities $ 8,956 $ 13,440

Fair value measurements (Tables

Fair value measurements (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Schedule of Financial instruments at fair value on a recurring basis	The following tables set forth the fair value of the Company’s consolidated financial instruments that were measured at fair value on a recurring basis (in thousands): December 31, 2018 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Level 1 Level 2 Level 3 Financial assets: Money market funds $ 93,934 $ — $ — $ 93,934 $ 93,934 $ — $ — Certificates of deposit 300 — — 300 — 300 — Commercial paper 10,908 — (1 ) 10,907 — 10,907 — U.S. treasury notes 9,990 — — 9,990 9,990 — — U.S. government agency securities 6,001 — (4 ) 5,997 — 5,997 — Total financial assets $ 121,133 $ — $ (5 ) $ 121,128 $ 103,924 $ 17,204 $ — Financial liabilities: Contingent consideration $ 4,998 $ — $ — $ 4,998 Total financial liabilities $ 4,998 $ — $ — $ 4,998 December 31, 2018 Reported as: Cash equivalents $ 101,395 Restricted cash 6,006 Marketable securities 13,727 Total cash equivalents, restricted cash, and marketable securities $ 121,128 Accrued liabilities $ 4,998 December 31, 2017 Amortized Gross Gross Estimated Level 1 Level 2 Level 3 Financial assets: Money market funds $ 5,998 $ — $ — $ 5,998 $ 5,998 $ — $ — Certificates of deposit 300 — — 300 300 — — U.S. treasury notes 12,010 — (19 ) 11,991 11,991 — — U.S. government agency securities 46,451 — (152 ) 46,299 — 46,299 — Total financial assets $ 64,759 $ — $ (171 ) $ 64,588 $ 18,289 $ 46,299 $ — Financial liabilities: Contingent consideration $ 3,779 $ — $ — $ 3,779 Total financial liabilities $ 3,779 $ — $ — $ 3,779 December 31, 2017 Reported as: Cash equivalents $ 592 Restricted cash 5,406 Marketable securities 58,590 Total cash equivalents, restricted cash, and marketable securities $ 64,588 Accrued liabilities $ 3,779
Schedule of Level 3 financial instruments measured at fair value on a recurring basis	The following table presents the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands): Level 3 Contingent Consideration Liability Balance as of December 31, 2017 $ 3,779 Change in estimate of fair value 1,219 Balance as of December 31, 2018 $ 4,998
Schedule of Carrying amount and the estimated fair value of the Company's outstanding debt	The carrying amount of the Company’s outstanding debt at December 31, 2018 approximated its fair value and as of December 31, 2017 , the Company's debt carrying amount and fair value were as follows (in thousands): December 31, 2017 Carrying Amount Fair Value Debt $ 39,084 $ 40,526

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum payments under operating leases	Future minimum payments under non-cancelable operating leases and future minimum payments to be received from non-cancelable subleases as of December 31, 2018 are as follows (in thousands): Amounts 2019 $ 10,948 2020 10,860 2021 11,109 2022 11,067 2023 8,898 Thereafter 25,715 Future non-cancelable minimum operating lease payments 78,597 Less: minimum payments to be received from non-cancelable subleases (174 ) Total future non-cancelable minimum operating lease payments, net $ 78,423
Schedule of rent expense related to non-cancelable operating leases	The following table summarizes rent expense related to non-cancelable operating leases (in thousands): Year Ended December 31, 2018 2017 2016 Rent expense $ 9,720 $ 8,950 $ 8,901 Sublease income 227 398 257 Rent expense, net of sublease income $ 9,493 $ 8,552 $ 8,644
Schedule of future payments under loan and security agreement	Future estimated payments under the 2018 Note Purchase Agreement as of December 31, 2018 are as follows (in thousands): Amounts 2019 $ 6,654 2020 8,297 2021 8,279 2022 8,279 2023 8,279 Thereafter 89,998 Total remaining payments 129,786 Less: amount representing debt discount (721 ) Less: amount representing interest (54,588 ) Total non-current debt obligation $ 74,477
Schedule of future minimum lease payments under capital leases	Future payments under capital leases at December 31, 2018 were as follows (in thousands): Amounts 2019 $ 2,087 2020 1,392 2021 21 Total capital lease obligations 3,500 Less: amount representing interest (188 ) Present value of net minimum capital lease payments 3,312 Less: current portion (1,937 ) Total non-current capital lease obligations $ 1,375
Schedule of future payments under noncancelable unconditional purchase commitments	At December 31, 2018 , the Company’s total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year were as follows (in thousands): Amount 2019 $ 3,040 2020 3,040 2021 1,440 Total $ 7,520

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Schedule of shares of common stock reserved for future issuance	As of December 31, 2018 and 2017 , the Company had reserved shares of common stock, on an as‑if converted basis, for issuance as follows (in thousands): As of December 31, 2018 2017 Options issued and outstanding 3,855 4,115 RSU awards issued and outstanding 4,031 2,387 Shares available for grant under stock option plans 118 2,397 Shares reserved for issuance under the 2015 Employee Stock Purchase Plan 278 308 Common stock underlying warrants 611 1,962 Common stock issuable upon conversion of preferred stock 3,459 3,459 Common stock underlying stock payable liabilities 132 689 Common stock payable as contingent consideration 452 551 Total 12,936 15,868
Schedule of outstanding warrants to purchase common stock	As of December 31, 2018 , the Company had outstanding warrants to purchase common stock as follows: Warrant Issuance Date Expiration Date Exercise Price Per Share Number of Shares of Common Stock Underlying Warrants Warrants issued in exchange for CombiMatrix Series F warrants November 2017 March 2021 $ 5.95 408,548 Warrants issued to lender under 2017 Loan Agreement March 2017 March 2027 $ 10.27 116,845 Warrants issued to lender under 2017 Loan Agreement - 2018 Amendments March 2018 March 2028 $ 7.02 85,482 610,875

Stock incentive plans (Tables)

Stock incentive plans (Tables)	12 Months Ended
	Dec. 31, 2018
Stock incentive plan
Schedule of activity under stock incentive plans	Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share amounts and years): Shares Available For Grant Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Balance at December 31, 2017 2,397 4,115 $ 8.51 7.6 $ 5,128 Additional shares reserved 754 — Options granted (260 ) 260 $ 8.50 Options cancelled 169 (169 ) $ 9.35 Options exercised — (351 ) $ 7.73 RSUs granted (3,282 ) — RSUs cancelled 340 — Balance at December 31, 2018 118 3,855 $ 8.54 6.8 $ 9,927 Options exercisable at December 31, 2018 2,737 $ 8.27 6.4 $ 7,787 Options vested and expected to vest at December 31, 2018 3,710 $ 8.52 6.8 $ 9,626
Summary of RSU activity	The following table summarizes RSU activity for the year ended December 31, 2018 (in thousands, except per share data: Number of Shares Weighted-Average Grant Date Fair Value Balance at December 31, 2017 2,387 $ 9.91 RSUs granted 3,282 $ 7.46 RSUs vested (1,298 ) $ 8.84 RSUs cancelled (340 ) $ 8.84 Balance at December 31, 2018 4,031 $ 8.35
Summary of stock based compensation expense related to stock options included in consolidated statements of operations	The following table summarizes stock-based compensation expense for the years ended December 31, 2018 , 2017 and 2016 , included in the consolidated statements of operations (in thousands): Year Ended December 31, 2018 2017 2016 Cost of revenue $ 2,960 $ 2,093 $ 1,353 Research and development 7,017 6,158 4,976 Selling and marketing 4,887 3,956 1,709 General and administrative 5,986 7,014 2,661 Total stock-based compensation expense $ 20,850 $ 19,221 $ 10,699
Employee Stock Option
Stock incentive plan
Schedule of assumptions used in determination of fair value of options	The fair value of share-based payments for stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model based on the following assumptions: Year Ended December 31, 2018 2017 2016 Expected term (in years) 6.00 6.03 6.03 Expected volatility 59.58% 72.64% 71.42% Risk-free interest rate 2.80% 2.01% 1.37%
Non-Employee Options
Stock incentive plan
Schedule of assumptions used in determination of fair value of options	The fair value of the stock options granted is calculated at each reporting date using the Black-Scholes option-pricing model based on the following assumptions: Year Ended December 31, 2018 2017 2016 Expected term (in years) — 8.41 – 8.83 6.25 – 10.00 Expected volatility — 69.9 – 78.70% 76.92% Risk-free interest rate — 1.83 – 2.04% 1.55 – 2.37%
2015 Employee Stock Purchase Plan
Stock incentive plan
Schedule of assumptions used in determination of fair value of options	The fair value of the shares purchased pursuant to the ESPP was estimated using the following assumptions: Year Ended December 31, 2018 2017 2016 Expected term (in years) 0.5 0.5 0.5 Expected volatility 71.66% 52.50% 66.31% Risk-free interest rate 2.09% 1.23% 0.50%

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of components of loss before income taxes by U.S. and foreign jurisdictions	The components of net loss before taxes by U.S. and foreign jurisdictions are as follows (in thousands): Year Ended December 31, 2018 2017 2016 United States $ 132,194 $ 124,108 $ 99,793 Foreign (39 ) 1,128 463 Total $ 132,155 $ 125,236 $ 100,256
Schedule of components of the provision for income taxes	The components of the provision for income taxes are as follows (in thousands): Year Ended December 31, 2018 2017 2016 Current: Foreign 62 — — Total current benefit for income taxes 62 — — Deferred: Federal (2,862 ) (1,704 ) — State — (152 ) — Total deferred benefit for income taxes (2,862 ) (1,856 ) — Total income tax benefit $ (2,800 ) $ (1,856 ) $ —
Schedule of reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense	The following table presents a reconciliation of the tax expense computed at the statutory federal rate and the Company’s tax expense for the periods presented: Year Ended December 31, 2018 2017 2016 U.S. federal taxes at statutory rate 21.0 % 34.0 % 34.0 % State taxes (net of federal benefit) 5.2 % 3.3 % 1.4 % Stock-based compensation (0.7 )% (1.1 )% (1.7 )% Research and development credits 2.7 % — % — % Non-deductible expenses (0.6 )% — % 0.2 % Foreign tax differential — % (0.3 )% (0.2 )% Other — % — % 1.1 % Change in valuation allowance (25.5 )% (34.4 )% (34.8 )% Change in deferred—Tax Reform — % (39.0 )% — % Change in valuation allowance—Tax Reform — % 39.0 % — % Total 2.1 % 1.5 % — %
Schedule of net deferred tax assets	The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands): As of December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 76,972 $ 70,825 Tax credits 15 15 Revenue recognition differences 47,650 29,819 Accruals and other 7,262 5,544 Gross deferred tax assets 131,899 106,203 Valuation allowance (121,954 ) (95,687 ) Total deferred tax assets 9,945 10,516 Deferred tax liabilities: Property and equipment (9,945 ) (10,516 ) Total deferred tax liabilities (9,945 ) (10,516 ) Net deferred tax assets $ — $ —
Schedule of reconciliation of gross unrecognized tax benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year ended December 31, 2018 2017 2016 Unrecognized tax benefits, beginning of period $ 10,561 $ 7,791 $ 11,429 Gross increases—current period tax positions 5,686 2,552 782 Gross increases (decreases)—prior period tax positions 128 218 (4,420 ) Unrecognized tax benefits, end of period $ 16,375 $ 10,561 $ 7,791

Net loss per common share (Tabl

Net loss per common share (Tables)	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Schedule of earnings per share, basic and diluted	The following table presents the calculation of basic and diluted net loss per share for the years ended December 31, 2018 , 2017 and 2016 (in thousands, except per share data): Year ended December 31, 2018 2017 2016 Net loss $ (129,355 ) $ (123,380 ) $ (100,256 ) Shares used in computing net loss per share, basic and diluted 66,747 46,512 33,176 Net loss per share, basic and diluted $ (1.94 ) $ (2.65 ) $ (3.02 )
Schedule of antidilutive securities excluded from computation of earnings per share	The following common stock equivalents have been excluded from diluted net loss per share for the years ended December 31, 2018 , 2017 and 2016 because their inclusion would be anti-dilutive (in thousands): Year Ended December 31, 2018 2017 2016 Shares of common stock subject to outstanding options 3,855 4,115 4,491 Shares of common stock subject to outstanding warrants 611 1,962 — Shares of common stock subject to outstanding RSUs 4,031 2,387 892 Shares of common stock subject to outstanding PRSUs — — 530 Shares of common stock pursuant to ESPP 63 59 55 Shares of common stock underlying Series A convertible preferred stock 3,459 3,459 — Total shares of common stock equivalents 12,019 11,982 5,968

Geographic information (Tables)

Geographic information (Tables)	12 Months Ended
	Dec. 31, 2018
Segments, Geographical Areas [Abstract]
Schedule of revenue by country	Revenue by country is determined based on the billing address of the customer and is summarized as follows (in thousands): Year Ended December 31, 2018 2017 2016 United States $ 138,239 $ 62,446 $ 20,758 Canada 4,206 3,226 2,526 Rest of world 5,254 2,549 1,764 Total revenue $ 147,699 $ 68,221 $ 25,048

Selected Quarterly Data (Unau_2

Selected Quarterly Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Schedule of selected quarterly data	The following table summarizes the Company's quarterly financial information for 2018 and 2017 (in thousands, except per share amounts): Three Months Ended March 31, 2018 June 30, 2018 September 30, 2018 December 31, 2018 Revenue $ 27,671 $ 37,306 $ 37,366 $ 45,356 Cost of revenue $ 18,076 $ 20,447 $ 20,441 $ 21,141 Loss from operations $ (36,475 ) $ (30,068 ) $ (30,110 ) $ (25,904 ) Net loss (2) $ (36,120 ) $ (31,671 ) $ (31,723 ) $ (29,841 ) Net loss per share, basic and diluted (1) $ (0.66 ) $ (0.47 ) $ (0.45 ) $ (0.40 ) Three Months Ended March 31, 2017 June 30, 2017 September 30, 2017 December 31, 2017 Revenue $ 10,338 $ 14,336 $ 18,148 $ 25,399 Cost of revenue $ 9,329 $ 10,490 $ 13,274 $ 17,049 Loss from operations $ (27,337 ) $ (28,075 ) $ (30,976 ) $ (34,891 ) Net loss (2) $ (26,928 ) $ (28,557 ) $ (27,402 ) $ (40,493 ) Net loss per share, basic and diluted (1) $ (0.64 ) $ (0.66 ) $ (0.57 ) $ (0.78 ) ___________________________________________________________________ (1) Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of quarterly net loss per share information may not equal annual net loss per share. (2) Includes $5.3 million

Organization and description _2

Organization and description of business - Narrative (Details) gene in Thousands	12 Months Ended
	Dec. 31, 2018Segmentgene
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of genes | gene	20
Number of operating segments | Segment	1

Summary of significant accoun_4

Summary of significant accounting policies - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Summary Of Significant Accounting Policies [Line Items]
Inventory	$ 8,300,000	$ 5,400,000
Intangible assets estimated useful lives	8 years 2 months 12 days
Goodwill impairment loss	$ 0	0	$ 0
Impairment losses	2,925,000	0	0
Long-lived asset impairment losses	0	0	0
Advertising expense	600,000	$ 600,000	500,000
Future undiscounted capital lease payments	3,500,000
Future undiscounted non-cancelable minimum operating lease payments	$ 78,423,000
Leasehold improvements | General and administrative
Summary Of Significant Accounting Policies [Line Items]
Impairment losses			$ 1,000,000
Customer relationships
Summary Of Significant Accounting Policies [Line Items]
Intangible assets estimated useful lives	10 years
Minimum
Summary Of Significant Accounting Policies [Line Items]
Intangible assets estimated useful lives	2 years
Property and equipment, estimated useful lives	3 years
Minimum | Customer relationships
Summary Of Significant Accounting Policies [Line Items]
Intangible assets estimated useful lives	5 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Intangible assets estimated useful lives	15 years
Property and equipment, estimated useful lives	7 years
Maximum | Customer relationships
Summary Of Significant Accounting Policies [Line Items]
Intangible assets estimated useful lives	11 years
Revenue | Customer concentration risk | Medicare
Summary Of Significant Accounting Policies [Line Items]
Concentration risk (as a percent)	22.00%	13.00%	11.00%
Revenue | Customer concentration risk | Medicare | Maximum
Summary Of Significant Accounting Policies [Line Items]
Concentration risk (as a percent)	10.00%
Accounts receivable | Customer concentration risk | Medicare
Summary Of Significant Accounting Policies [Line Items]
Concentration risk (as a percent)	21.00%	13.00%

Summary of significant accoun_5

Summary of significant accounting policies - Schedule of significant customers, revenue as a percentage (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Customer concentration risk | Revenue | Medicare
Product Information [Line Items]
Concentration risk (as a percent)	22.00%	13.00%	11.00%

Summary of significant accoun_6

Summary of significant accounting policies - Schedule of cash, cash equivalents and restricted cash (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Cash and cash equivalents	$ 112,158	$ 12,053
Restricted cash	6,006	5,406
Total cash, cash equivalents and restricted cash	$ 118,164	$ 17,459	$ 71,522	$ 78,069

Summary of significant accoun_7

Summary of significant accounting policies - Schedule of useful lives of property and equipment (Details)	12 Months Ended
	Dec. 31, 2018
Furniture and fixtures
Property and equipment
Useful lives	7 years
Automobiles
Property and equipment
Useful lives	7 years
Laboratory equipment
Property and equipment
Useful lives	5 years
Computer equipment
Property and equipment
Useful lives	3 years
Software
Property and equipment
Useful lives	3 years

Revenue, accounts receivable _3

Revenue, accounts receivable and deferred revenue - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 01, 2018	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disaggregation of Revenue [Line Items]
Cumulative effect of accounting change	$ 11,241
Revenue recognized										$ 300
Total revenue		$ 45,356	$ 37,366	$ 37,306	$ 27,671	$ 25,399	$ 18,148	$ 14,336	$ 10,338	147,699	$ 68,221	$ 25,048
Loss from operations		$ (25,904)	$ (30,110)	$ (30,068)	$ (36,475)	$ (34,891)	$ (30,976)	$ (28,075)	$ (27,337)	$ (122,557)	$ (121,279)	$ (100,183)
Net loss per share, basic and diluted (in dollars per share)		$ (0.40)	$ (0.45)	$ (0.47)	$ (0.66)	$ (0.78)	$ (0.57)	$ (0.66)	$ (0.64)	$ (1.94)	$ (2.65)	$ (3.02)
Topic 606
Disaggregation of Revenue [Line Items]
Cumulative effect of accounting change	$ 11,200
Test revenue
Disaggregation of Revenue [Line Items]
Total revenue										$ 144,560	$ 65,169	$ 24,840
Test revenue | Change in estimate of revenue recognition
Disaggregation of Revenue [Line Items]
Total revenue										4,500
Loss from operations										$ 4,500
Net loss per share, basic and diluted (in dollars per share)										$ 0.07
Maximum
Disaggregation of Revenue [Line Items]
Performance obligations underlying contracts period	1 year
Sales commissions amortization period	1 year
Period of payments to be received for goods or service	1 year

Revenue, accounts receivable _4

Revenue, accounts receivable and deferred revenue - Schedule of impact of adoption of topic 606 on condensed statement of operations and balance sheet (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 45,356	$ 37,366	$ 37,306	$ 27,671	$ 25,399	$ 18,148	$ 14,336	$ 10,338	$ 147,699	$ 68,221	$ 25,048
Net loss	$ (29,841)	$ (31,723)	$ (31,671)	$ (36,120)	$ (40,493)	$ (27,402)	$ (28,557)	$ (26,928)	$ (129,355)	$ (123,380)	$ (100,256)
Net loss per share, basic and diluted (in dollars per share)	$ (0.40)	$ (0.45)	$ (0.47)	$ (0.66)	$ (0.78)	$ (0.57)	$ (0.66)	$ (0.64)	$ (1.94)	$ (2.65)	$ (3.02)
Accounts receivable	$ 26,296				$ 10,422				$ 26,296	$ 10,422
Accumulated deficit	(516,712)				(398,598)				(516,712)	(398,598)
Stockholders' equity	161,839				$ 121,794				161,839	121,794	$ 99,074	$ 138,376
Without adoption of topic 606 | Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Net loss									$ (129,693)
Net loss per share, basic and diluted (in dollars per share)									$ (1.94)
Accounts receivable	14,150								$ 14,150
Accumulated deficit	(528,291)								(528,291)
Stockholders' equity	150,260								150,260
Effect of adoption higher/lower | Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Net loss									$ 338
Net loss per share, basic and diluted (in dollars per share)									$ 0
Accounts receivable	12,146								$ 12,146
Accumulated deficit	11,579								11,579
Stockholders' equity	$ 11,579								11,579
Test revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue									144,560	$ 65,169	$ 24,840
Test revenue | Without adoption of topic 606 | Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue									144,222
Test revenue | Effect of adoption higher/lower | Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue									$ 338

Revenue, accounts receivable _5

Revenue, accounts receivable and deferred revenue - Schedule of disaggregated revenue by payer category (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disaggregation of Revenue [Line Items]
Total revenue	$ 45,356	$ 37,366	$ 37,306	$ 27,671	$ 25,399	$ 18,148	$ 14,336	$ 10,338	$ 147,699	$ 68,221	$ 25,048
Test revenue
Disaggregation of Revenue [Line Items]
Total revenue									144,560	65,169	24,840
Test revenue | Institutions
Disaggregation of Revenue [Line Items]
Total revenue									34,618	17,238
Test revenue | Patient - direct
Disaggregation of Revenue [Line Items]
Total revenue									13,589	5,638
Test revenue | Patient - insurance
Disaggregation of Revenue [Line Items]
Total revenue									96,353	42,293
Other revenue
Disaggregation of Revenue [Line Items]
Total revenue									$ 3,139	$ 3,052	$ 208

Business combinations - Narrati

Business combinations - Narrative (Details) - USD ($)

Mar. 31, 2019

Mar. 31, 2018

Nov. 14, 2017

Aug. 04, 2017

Jul. 31, 2017

Jun. 11, 2017

Jan. 06, 2017

Jan. 31, 2019

Sep. 30, 2018

Jun. 30, 2018

Apr. 30, 2018

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Business Acquisition [Line Items]

Intangible assets estimated useful lives

8 years 2 months 12 days

Goodwill

$ 50,095,000

$ 46,575,000

Decrease in accounts receivable

(5,291,000)

(1,963,000)

$ (843,000)

Goodwill adjustment

$ 3,520,000

Non-compete agreement

Business Acquisition [Line Items]

Intangible assets estimated useful lives

5 years

Customer relationships

Business Acquisition [Line Items]

Intangible assets estimated useful lives

10 years

Maximum

Business Acquisition [Line Items]

Intangible assets estimated useful lives

15 years

Maximum | Customer relationships

Business Acquisition [Line Items]

Intangible assets estimated useful lives

11 years

AltaVoice

Business Acquisition [Line Items]

Total purchase consideration

$ 12,400,000

Payment through issuance of shares company's common stock

5,500,000

Contingently payable amount

$ 5,000,000

Purchase consideration, second payment discounted and recorded as liability

4,700,000

Change in fair value of contingent consideration

2,200,000

Goodwill acquired

$ 9,400,000

Goodwill

9,432,000

9,432,000

9,432,000

Goodwill adjustment

$ 0

Deferred tax liability

$ 1,422,000

AltaVoice | Non-compete agreement

Business Acquisition [Line Items]

Intangible assets estimated useful lives

5 years

10 years

AltaVoice | Customer relationships

Business Acquisition [Line Items]

Intangible assets estimated useful lives

10 years

AltaVoice | Other (income) expense

Business Acquisition [Line Items]

Accretion gains (losses)

$ 1,600,000

(200,000)

AltaVoice | General and administrative

Business Acquisition [Line Items]

Change in estimate of fair value

1,200,000

1,600,000

AltaVoice | Milestone Based on Certain Threshold of Revenue Achieved During 2017 [Member]

Business Acquisition [Line Items]

Common stock issued, value

5,000,000

AltaVoice | Scenario, forecast | New Contingent Milestone Based On Achieving Revenue Target During 2017 And 2018

Business Acquisition [Line Items]

Contingent consideration, revenue target for payout

$ 14,000,000

Contingent consideration, revenue target (as a percent)

75.00%

Contingent consideration, amount deducted on revenue target

$ 5,500,000

Business combination possible payout amount

5,000,000

AltaVoice | Scenario, forecast | New Contingent Milestone Based On Achieving Revenue Target During 2017 And 2018 | Maximum

Business Acquisition [Line Items]

Common stock issued, value

$ 5,000,000

AltaVoice | Common stock

Business Acquisition [Line Items]

Payment through issuance of shares company's common stock

5,000,000

$ 5,500,000

Common stock issued (in shares)

641,126

716,332

Common stock issued, value

$ 5,000,000

AltaVoice | Common stock | Maximum

Business Acquisition [Line Items]

Contingently payable amount

5,000,000

Ommdom, Inc.

Business Acquisition [Line Items]

Total purchase consideration

$ 6,100,000

Payment through issuance of shares company's common stock

5,500,000

Purchase consideration, second payment discounted and recorded as liability

600,000

Hold-back consideration amount

600,000

Goodwill

4,045,000

4,045,000

4,045,000

Goodwill adjustment

0

Deferred tax liability

$ 434,000

Ommdom, Inc. | Customer relationships

Business Acquisition [Line Items]

Intangible assets estimated useful lives

5 years

Ommdom, Inc. | Common stock

Business Acquisition [Line Items]

Payment through issuance of shares company's common stock

$ 5,500,000

Common stock issued (in shares)

600,108

Hold-back consideration amount

$ 600,000

Common stock issued, related to hold back (in shares)

66,582

66,582

Good Start Genetics

Business Acquisition [Line Items]

Total purchase consideration

$ 24,400,000

Percentage of diluted interest acquired

100.00%

Goodwill

$ 25,064,000

25,064,000

24,406,000

Cash consideration

18,400,000

Provisional deferred tax liability

$ 4,800,000

Decrease in accounts receivable

700,000

Goodwill adjustment

$ 658,000

Good Start Genetics | Customer relationships

Business Acquisition [Line Items]

Intangible assets estimated useful lives

8 years

8 years

Good Start Genetics | Common stock

Business Acquisition [Line Items]

Hold-back consideration amount

$ 3,600,000

Common stock issued, related to hold back (in shares)

343,986

212,260

Equity interests issued for settlement of convertible debt

$ 11,900,000

Equity interests issued for settlement of convertible debt (in shares)

1,148,283

Remaining hold-back amount payable to settle outstanding claims

$ 1,300,000

Remaining hold back amount payable to settle bonuses

200,000

Good Start Genetics | Common stock | General and administrative

Business Acquisition [Line Items]

Payment through issuance of shares company's common stock

$ 900,000

Common stock issued (in shares)

83,025

Payment by issuance of common stock to settle bonuses

$ 400,000

Issuance of common stock to settle bonuses (in shares)

37,406

27,784

CombiMatrix

Business Acquisition [Line Items]

Common stock issued (in shares)

2,703,389

Goodwill

$ 11,554,000

11,554,000

$ 8,692,000

Goodwill adjustment

2,862,000

Trailing average share value (in dollars per share)

$ 9.491

Deferred tax liability

$ 2,862,000

$ 2,900,000

CombiMatrix | Series F Preferred Stock

Business Acquisition [Line Items]

Payment through issuance of shares company's common stock

$ 100,000

Common stock issued (in shares)

3,144

CombiMatrix | Series F Warrants

Business Acquisition [Line Items]

Payment through issuance of shares company's common stock

$ 7,400,000

Common stock issued (in shares)

1,739,689

CombiMatrix | Series D Warrants

Business Acquisition [Line Items]

Payment through issuance of shares company's common stock

$ 1,000

Common stock issued (in shares)

337,584

CombiMatrix | Restricted Stock Units (RSUs)

Business Acquisition [Line Items]

Payment through issuance of shares company's common stock

$ 700,000

Common stock issued (in shares)

85,219

CombiMatrix | Shares of common stock subject to outstanding options

Business Acquisition [Line Items]

Payment through issuance of shares company's common stock

$ 100,000

Common stock issued (in shares)

3,323

CombiMatrix | Common stock

Business Acquisition [Line Items]

Business combination common stock conversion ratio

86.92%

CombiMatrix | Shares of common stock subject to outstanding warrants

Business Acquisition [Line Items]

Common stock issued (in shares)

2,077,273

CombiMatrix | Customer relationships

Business Acquisition [Line Items]

Intangible assets estimated useful lives

11 years

11 years

CombiMatrix | General and administrative | Common stock | Restricted Stock Units (RSUs)

Business Acquisition [Line Items]

Payment through issuance of shares company's common stock

$ 1,700,000

Common stock issued (in shares)

214,976

CombiMatrix | Common stock

Business Acquisition [Line Items]

Payment through issuance of shares company's common stock

$ 20,500,000

Common stock issued (in shares)

2,611,703

CombiMatrix | Common stock | General and administrative

Business Acquisition [Line Items]

Payment through issuance of shares company's common stock

$ 200,000

Common stock issued (in shares)

22,966

Subsequent event | Good Start Genetics | Common stock

Business Acquisition [Line Items]

Hold-back consideration amount

$ 600,000

Subsequent event | Good Start Genetics | Common stock | General and administrative

Business Acquisition [Line Items]

Payment by issuance of common stock to settle bonuses

$ 100,000

Business combinations - Summary

Business combinations - Summary of fair values of assets acquired and liabilities assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Nov. 14, 2017	Aug. 04, 2017	Jun. 11, 2017	Jan. 06, 2017
Business Acquisition [Line Items]
Goodwill	$ 50,095	$ 46,575
AltaVoice
Business Acquisition [Line Items]
Cash						$ 54
Accounts receivable						274
Prepaid expense and other assets						52
Total identifiable assets acquired						4,625
Accounts payable						(28)
Deferred revenue						(202)
Accrued expenses						(21)
Deferred tax liability						(1,422)
Total liabilities assumed						(1,673)
Net identifiable assets acquired						2,952
Goodwill	9,432	9,432				9,432
Net assets acquired						12,384
AltaVoice | Non-compete agreement
Business Acquisition [Line Items]
Intangible Assets						286
AltaVoice | Developed technology
Business Acquisition [Line Items]
Intangible Assets						570
AltaVoice | Customer relationships
Business Acquisition [Line Items]
Intangible Assets						$ 3,389
Ommdom, Inc.
Business Acquisition [Line Items]
Cash					$ 53
Accounts receivable					10
Prepaid expense and other assets					4
Total identifiable assets acquired					2,562
Accounts payable					(16)
Accrued expenses					(17)
Deferred tax liability					(434)
Total liabilities assumed					(467)
Net identifiable assets acquired					2,095
Goodwill	4,045	4,045			4,045
Net assets acquired					6,140
Ommdom, Inc. | Trade name
Business Acquisition [Line Items]
Intangible Assets					13
Ommdom, Inc. | Developed technology
Business Acquisition [Line Items]
Intangible Assets					2,335
Ommdom, Inc. | Customer relationships
Business Acquisition [Line Items]
Intangible Assets					$ 147
Good Start Genetics
Business Acquisition [Line Items]
Cash and restricted cash				$ 1,381
Accounts receivable				2,246
Prepaid expense and other assets				1,579
Property and equipment				1,320
Total identifiable assets acquired				20,712
Accounts payable				(5,418)
Accrued expenses				(6,802)
Notes payable				(17,904)
Convertible promissory notes payable				(15,430)
Other liabilities				(222)
Total liabilities assumed				(45,776)
Net identifiable assets acquired				(25,064)
Goodwill	25,064	24,406		25,064
Net assets acquired				0
Good Start Genetics | Trade name
Business Acquisition [Line Items]
Intangible Assets				460
Good Start Genetics | Developed technology
Business Acquisition [Line Items]
Intangible Assets				5,896
Good Start Genetics | Customer relationships
Business Acquisition [Line Items]
Intangible Assets				$ 7,830
CombiMatrix
Business Acquisition [Line Items]
Cash and restricted cash			$ 1,333
Accounts receivable			4,118
Prepaid expense and other assets			1,299
Property and equipment			437
Other assets - non current			30
Total identifiable assets acquired			23,622
Accounts payable			(276)
Accrued expenses			(3,925)
Deferred tax liability	(2,900)		(2,862)
Other liabilities			(180)
Total liabilities assumed			(7,243)
Net identifiable assets acquired			16,379
Goodwill	$ 11,554	$ 8,692	11,554
Net assets acquired			27,933
CombiMatrix | Favorable leases
Business Acquisition [Line Items]
Intangible Assets			247
CombiMatrix | Trade name
Business Acquisition [Line Items]
Intangible Assets			103
CombiMatrix | Patent licensing agreement
Business Acquisition [Line Items]
Intangible Assets			496
CombiMatrix | Developed technology
Business Acquisition [Line Items]
Intangible Assets			3,162
CombiMatrix | Customer relationships
Business Acquisition [Line Items]
Intangible Assets			$ 12,397

Business combinations - Schedul

Business combinations - Schedule of economic benefits of intangible assets expected to be realized (Details) - USD ($) $ in Thousands	Nov. 14, 2017	Aug. 04, 2017	Jun. 11, 2017	Jan. 06, 2017	Dec. 31, 2018
Business Acquisition [Line Items]
Gross Purchased Intangible Assets					$ 37,331
Intangible assets estimated useful lives					8 years 2 months 12 days
Non-compete agreement
Business Acquisition [Line Items]
Gross Purchased Intangible Assets					$ 286
Intangible assets estimated useful lives					5 years
Trade name
Business Acquisition [Line Items]
Gross Purchased Intangible Assets					$ 576
Intangible assets estimated useful lives					2 years 8 months 12 days
Patent licensing agreement
Business Acquisition [Line Items]
Gross Purchased Intangible Assets					$ 496
Intangible assets estimated useful lives					15 years
Developed technology
Business Acquisition [Line Items]
Gross Purchased Intangible Assets					$ 11,963
Intangible assets estimated useful lives					4 years 9 months 18 days
Customer relationships
Business Acquisition [Line Items]
Gross Purchased Intangible Assets					$ 23,763
Intangible assets estimated useful lives					10 years
AltaVoice
Business Acquisition [Line Items]
Gross Purchased Intangible Assets				$ 4,245
AltaVoice | Non-compete agreement
Business Acquisition [Line Items]
Gross Purchased Intangible Assets				$ 286
Intangible assets estimated useful lives				5 years	10 years
AltaVoice | Developed technology
Business Acquisition [Line Items]
Gross Purchased Intangible Assets				$ 570
Intangible assets estimated useful lives				6 years
AltaVoice | Customer relationships
Business Acquisition [Line Items]
Gross Purchased Intangible Assets				$ 3,389
Intangible assets estimated useful lives				10 years
Ommdom, Inc.
Business Acquisition [Line Items]
Gross Purchased Intangible Assets			$ 2,495
Ommdom, Inc. | Trade name
Business Acquisition [Line Items]
Gross Purchased Intangible Assets			$ 13
Intangible assets estimated useful lives			5 years
Ommdom, Inc. | Developed technology
Business Acquisition [Line Items]
Gross Purchased Intangible Assets			$ 2,335
Intangible assets estimated useful lives			5 years
Ommdom, Inc. | Customer relationships
Business Acquisition [Line Items]
Gross Purchased Intangible Assets			$ 147
Intangible assets estimated useful lives			5 years
Good Start Genetics
Business Acquisition [Line Items]
Gross Purchased Intangible Assets		$ 14,186
Good Start Genetics | Trade name
Business Acquisition [Line Items]
Gross Purchased Intangible Assets		$ 460
Intangible assets estimated useful lives		3 years
Good Start Genetics | Developed technology
Business Acquisition [Line Items]
Gross Purchased Intangible Assets		$ 5,896
Intangible assets estimated useful lives		5 years
Good Start Genetics | Customer relationships
Business Acquisition [Line Items]
Gross Purchased Intangible Assets		$ 7,830
Intangible assets estimated useful lives		8 years			8 years
CombiMatrix
Business Acquisition [Line Items]
Gross Purchased Intangible Assets	$ 16,405
CombiMatrix | Favorable leases
Business Acquisition [Line Items]
Gross Purchased Intangible Assets	$ 247
Intangible assets estimated useful lives	2 years
CombiMatrix | Trade name
Business Acquisition [Line Items]
Gross Purchased Intangible Assets	$ 103
Intangible assets estimated useful lives	1 year
CombiMatrix | Patent licensing agreement
Business Acquisition [Line Items]
Gross Purchased Intangible Assets	$ 496
Intangible assets estimated useful lives	15 years
CombiMatrix | Developed technology
Business Acquisition [Line Items]
Gross Purchased Intangible Assets	$ 3,162
Intangible assets estimated useful lives	4 years
CombiMatrix | Customer relationships
Business Acquisition [Line Items]
Gross Purchased Intangible Assets	$ 12,397
Intangible assets estimated useful lives	11 years				11 years

Goodwill and intangible asset_2

Goodwill and intangible assets - Summary of goodwill (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Goodwill [Roll Forward]
December 31, 2017	$ 46,575
Goodwill adjustment	3,520
December 31, 2018	50,095
AltaVoice
Goodwill [Roll Forward]
December 31, 2017	9,432
Goodwill adjustment	0
December 31, 2018	9,432
Ommdom
Goodwill [Roll Forward]
December 31, 2017	4,045
Goodwill adjustment	0
December 31, 2018	4,045
Good Start
Goodwill [Roll Forward]
December 31, 2017	24,406
Goodwill adjustment	658
December 31, 2018	25,064
CombiMatrix
Goodwill [Roll Forward]
December 31, 2017	8,692
Goodwill adjustment	2,862
December 31, 2018	$ 11,554

Goodwill and intangible asset_3

Goodwill and intangible assets - Narrative (Details) - USD ($) $ in Thousands	Nov. 14, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Line Items]
Goodwill adjustment		$ 3,520
Intangible assets estimated useful lives		8 years 2 months 12 days
Amortization expense		$ 5,000	$ 1,800
Minimum
Goodwill [Line Items]
Intangible assets estimated useful lives		2 years
Maximum
Goodwill [Line Items]
Intangible assets estimated useful lives		15 years
Customer relationships
Goodwill [Line Items]
Intangible assets estimated useful lives		10 years
Customer relationships | Minimum
Goodwill [Line Items]
Intangible assets estimated useful lives		5 years
Customer relationships | Maximum
Goodwill [Line Items]
Intangible assets estimated useful lives		11 years
CombiMatrix
Goodwill [Line Items]
Goodwill adjustment		$ 2,862
CombiMatrix | Customer relationships
Goodwill [Line Items]
Intangible assets estimated useful lives	11 years	11 years

Goodwill and intangible asset_4

Goodwill and intangible assets - Schedule of finite-lived intangible assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Cost	$ 37,331
Accumulated Amortization	(6,862)
Net	$ 30,469	$ 35,516
Weighted Average Useful Life (in Years)	8 years 2 months 12 days
Weighted Average Estimated Remaining Useful Life (in Years)	6 years 9 months 18 days
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Cost	$ 23,763
Accumulated Amortization	(2,783)
Net	$ 20,980
Weighted Average Useful Life (in Years)	10 years
Weighted Average Estimated Remaining Useful Life (in Years)	8 years 7 months 6 days
Developed technology
Finite-Lived Intangible Assets [Line Items]
Cost	$ 11,963
Accumulated Amortization	(3,482)
Net	$ 8,481
Weighted Average Useful Life (in Years)	4 years 9 months 18 days
Weighted Average Estimated Remaining Useful Life (in Years)	3 years 4 months 24 days
Non-compete agreement
Finite-Lived Intangible Assets [Line Items]
Cost	$ 286
Accumulated Amortization	(114)
Net	$ 172
Weighted Average Useful Life (in Years)	5 years
Weighted Average Estimated Remaining Useful Life (in Years)	3 years
Trade name
Finite-Lived Intangible Assets [Line Items]
Cost	$ 576
Accumulated Amortization	(329)
Net	$ 247
Weighted Average Useful Life (in Years)	2 years 8 months 12 days
Weighted Average Estimated Remaining Useful Life (in Years)	1 year 4 months 24 days
Patent licensing agreement
Finite-Lived Intangible Assets [Line Items]
Cost	$ 496
Accumulated Amortization	(37)
Net	$ 459
Weighted Average Useful Life (in Years)	15 years
Weighted Average Estimated Remaining Useful Life (in Years)	13 years 10 months 24 days
Favorable leases
Finite-Lived Intangible Assets [Line Items]
Cost	$ 247
Accumulated Amortization	(117)
Net	$ 130
Weighted Average Useful Life (in Years)	2 years 2 months 12 days
Weighted Average Estimated Remaining Useful Life (in Years)	1 year 1 month 6 days

Goodwill and intangible asset_5

Goodwill and intangible assets - Summary of estimated future amortization expense of intangible assets with finite lives (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
2,019	$ 5,250
2,020	5,525
2,021	5,829
2,022	4,124
2,023	3,111
Thereafter	6,630
Net	$ 30,469	$ 35,516

Balance sheet components - Prop

Balance sheet components - Property and equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property and equipment
Total property and equipment, gross	$ 52,395	$ 49,871
Accumulated depreciation and amortization	(24,509)	(19,530)
Total property and equipment, net	27,886	30,341
Depreciation	8,500	7,200	$ 6,600
Leasehold improvements
Property and equipment
Total property and equipment, gross	13,034	12,623
Laboratory equipment
Property and equipment
Total property and equipment, gross	22,149	17,705
Equipment under capital lease
Property and equipment
Total property and equipment, gross	7,129	11,446
Computer equipment
Property and equipment
Total property and equipment, gross	4,723	4,023
Software
Property and equipment
Total property and equipment, gross	2,594	2,520
Furniture and fixtures
Property and equipment
Total property and equipment, gross	784	569
Automobiles
Property and equipment
Total property and equipment, gross	20	20
Construction-in-progress
Property and equipment
Total property and equipment, gross	$ 1,962	$ 965

Balance sheet components - Accr

Balance sheet components - Accrued liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Balance Sheet Related Disclosures [Abstract]
Accrued compensation and related expenses	$ 7,917	$ 7,406
Deferred revenue	761	307
Liabilities associated with business combinations	6,460	9,497
Liability associated with co-development agreement	2,000	0
Other	9,425	5,532
Total accrued liabilities	$ 26,563	$ 22,742

Balance sheet components - Othe

Balance sheet components - Other long-term liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Balance Sheet Related Disclosures [Abstract]
Lease incentive obligation, non-current	$ 3,280	$ 3,831
Deferred rent, non-current	5,495	5,153
Liabilities associated with business combinations	0	3,779
Other non-current liabilities	181	677
Total other long-term liabilities	$ 8,956	$ 13,440

Fair value measurements - Finan

Fair value measurements - Financial instruments at fair value on a recurring basis (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, amortized cost	$ 121,133	$ 64,759
Cash equivalents, restricted cash and marketable securities, gross unrealized loss before tax	(5)	(171)
Cash equivalents, restricted cash and marketable securities, estimated fair value	121,128	64,588
Cash equivalents	101,395	592
Restricted cash	6,006	5,406
Marketable securities	13,727	58,590
Accrued liabilities	26,563	22,742
Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	121,128	64,588
Total financial liabilities	4,998	3,779
Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	103,924	18,289
Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	17,204	46,299
Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	4,998	3,779
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, amortized cost	93,934	5,998
Money market funds | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, estimated fair value	93,934	5,998
Money market funds | Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, estimated fair value	93,934	5,998
Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, amortized cost	300	300
Certificates of deposit | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, estimated fair value	300	300
Certificates of deposit | Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, estimated fair value	0	300
Certificates of deposit | Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, estimated fair value	300
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, amortized cost	10,908
Cash equivalents, restricted cash and marketable securities, gross unrealized loss before tax	(1)
Commercial paper | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, estimated fair value	10,907
Commercial paper | Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, estimated fair value	0
Commercial paper | Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, estimated fair value	10,907
U.S. treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, amortized cost	9,990	12,010
Cash equivalents, restricted cash and marketable securities, gross unrealized loss before tax		(19)
U.S. treasury notes | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, estimated fair value	9,990	11,991
U.S. treasury notes | Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, estimated fair value	9,990	11,991
U.S. government agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, amortized cost	6,001	46,451
Cash equivalents, restricted cash and marketable securities, gross unrealized loss before tax	(4)	(152)
U.S. government agency securities | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, estimated fair value	5,997	46,299
U.S. government agency securities | Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, restricted cash and marketable securities, estimated fair value	5,997	46,299
Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued liabilities	4,998	3,779
Contingent consideration | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	4,998	3,779
Contingent consideration | Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	$ 4,998	$ 3,779

Fair value measurements - Narra

Fair value measurements - Narrative (Details) - USD ($)	Jan. 06, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2019	Mar. 31, 2018	Jan. 31, 2017
Fair Value, Option, Quantitative Disclosures [Line Items]
Transfers of assets and liabilities between Level 1, Level 2 and Level 3		$ 0	$ 0
Total fair value of investments with unrealized losses		13,400,000
Available-for-sale securities gross realized gain (loss)		0	$ 0	$ 0
AltaVoice
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingently payable amount						$ 5,000,000
Increase in fair value of contingent consideration	$ 2,200,000
AltaVoice | Common stock
Fair Value, Option, Quantitative Disclosures [Line Items]
Common stock issued, value						$ 5,000,000
AltaVoice | Maximum | Common stock
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingently payable amount		5,000,000
AltaVoice | Maximum | New Contingent Milestone Based On Achieving Revenue Target During 2017 And 2018 | Scenario, forecast
Fair Value, Option, Quantitative Disclosures [Line Items]
Common stock issued, value					$ 5,000,000
AltaVoice | Minimum | New Contingent Milestone Based On Achieving Revenue Target During 2017 And 2018 | Scenario, forecast
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent revenue threshold					$ 10,000,000
Contingent consideration | AltaVoice | Level 3 | Recurring basis
Fair Value, Option, Quantitative Disclosures [Line Items]
Estimated fair value for contingent consideration							$ 2,200,000
Increase in fair value of contingent consideration		$ 2,800,000

Fair value measurements - Level

Fair value measurements - Level 3 financial instruments measured at fair value on a recurring basis (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
AltaVoice | General and administrative
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in estimate of fair value	$ 1,200	$ 1,600
AltaVoice | General and administrative | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in estimate of fair value	1,219
Contingent consideration | Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
December 31, 2017	3,779
December 31, 2018	$ 4,998	$ 3,779

Fair value measurements - Carry

Fair value measurements - Carrying amount and the estimated fair value of the Company's outstanding debt (Details) - Recurring basis - Level 2 $ in Thousands	Dec. 31, 2017USD ($)
Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt	$ 39,084
Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt	$ 40,526

Investment in privately held _2

Investment in privately held company (Details) $ in Millions	12 Months Ended
	Dec. 31, 2018USD ($)
KEW
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Loss on license agreement	$ 2.9

Commitments and contingencies -

Commitments and contingencies - Operating leases narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2015
Operating Leased Assets [Line Items]
Total minimum lease payments	$ 78,597
Office Facility In San Francisco | New leases
Operating Leased Assets [Line Items]
Additional term of lease		10 years
Lease term		10 years
Security deposit		$ 4,600
Lease incentive in form of lease improvements		$ 5,200
Total minimum lease payments	$ 57,800

Commitments and contingencies_2

Commitments and contingencies - Schedule of future minimum payments under operating leases (Details) $ in Thousands	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,019	$ 10,948
2,020	10,860
2,021	11,109
2,022	11,067
2,023	8,898
Thereafter	25,715
Future non-cancelable minimum operating lease payments	78,597
Less: minimum payments to be received from non-cancelable subleases	(174)
Total future non-cancelable minimum operating lease payments, net	$ 78,423

Commitments and contingencies_3

Commitments and contingencies - Schedule of rent expense related to non-cancelable operating leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 9,720	$ 8,950	$ 8,901
Sublease income	227	398	257
Rent expense, net of sublease income	$ 9,493	$ 8,552	$ 8,644

Commitments and contingencies_4

Commitments and contingencies - Debt financing narrative (Details) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Nov. 30, 2018	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jan. 01, 2020	Mar. 31, 2018
Debt Instrument [Line Items]
Debt extinguishment costs				$ 4,609,000	$ 0	$ 0
Common stock, par value (in dollars per share)			$ 0.0001	$ 0.0001	$ 0.0001
Common stock issued pursuant to Securities Purchase Agreement (see Note 9)				$ 5,353,000
Note Purchase Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 200,000,000
Debt instrument, term	7 years
Debt instrument, interest rate, stated percentage			8.75%	8.75%
Internal rate of return percentage				11.00%
Debt instrument, average effective interest rate				10.60%
Note Purchase Agreement | Payment made within 12 months after closing date
Debt Instrument [Line Items]
Term loans, fee percentage of funded draw				117.50%
Note Purchase Agreement | Payment made within 24 months after closing date
Debt Instrument [Line Items]
Term loans, fee percentage of funded draw				132.50%
Note Purchase Agreement | Payment made within 36 months after closing date
Debt Instrument [Line Items]
Term loans, fee percentage of funded draw				145.00%
Note Purchase Agreement | Scenario, forecast
Debt Instrument [Line Items]
Percentage of net annual revenue receivable by purchasers in addition to interest, beginning on January 1, 2020							0.50%
Maximum net annual revenue receivable by purchasers in addition to interest, beginning on January 1, 2020							$ 1,600,000
Loan and Security Agreement | Initial term loan
Debt Instrument [Line Items]
Term loan, borrowing amount		$ 40,000,000
Net proceeds from term loan		39,700,000
Loan and Security Agreement | Second Term Loan
Debt Instrument [Line Items]
Term loan, borrowing amount								$ 20,000,000
Net proceeds from term loan		$ 19,800,000
Loan and Security Agreement | Third Term Loan
Debt Instrument [Line Items]
Term loan, borrowing amount			$ 20,000,000	$ 20,000,000
Loan and Security Agreement | Secured Debt
Debt Instrument [Line Items]
Term loan, line fee percentage on unused commitment amount			1.00%	1.00%
Term loan, line fee on unused commitment amount			$ 200,000	$ 200,000
Term loans, variable interest rate		7.73%
Term loans, index interest rate, minimum		0.77%
Term loans, frequency of periodic payment		monthly
Term loans, floor interest rate		8.50%
Term loans, fee percentage of funded draw		5.00%
Term loans, facility fee percentage		0.50%
Warrants issued to acquire shares, percentage of funded amount		3.00%
Warrants issued to purchase shares of common stock (in shares)		116,845
Warrants issued to purchase common stock exercise price (in dollars per share)		$ 10.27
Fair value of warrant		$ 700,000
Repayments of Long-term Debt	$ 64,700,000			75,000,000
Debt extinguishment costs			$ 5,300,000
Debt issuance cost				700,000
Interest expense				$ 6,700,000	$ 3,500,000	$ 300,000
Loan and Security Agreement | Secured Debt | Minimum
Debt Instrument [Line Items]
Term loans, prepayment fee percentage of outstanding balance		1.00%
Loan and Security Agreement | Secured Debt | Maximum
Debt Instrument [Line Items]
Term loans, prepayment fee percentage of outstanding balance		3.00%
Loan and Security Agreement | Secured Debt | Second Term Loan
Debt Instrument [Line Items]
Warrants issued to purchase shares of common stock (in shares)		85,482
Warrants issued to purchase common stock exercise price (in dollars per share)		$ 7.02
Fair value of warrant		$ 400,000
Warrants term		10 years
Initial sale of notes | Note Purchase Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity	75,000,000
Proceeds from Notes Payable	$ 10,300,000
Common stock
Debt Instrument [Line Items]
Common stock issued during period (in shares)				17,103,000		8,433,000
Common stock | Note Purchase Agreement
Debt Instrument [Line Items]
Common stock issued during period (in shares)	373,524
Shares issued price per share (in dollars per share)	$ 13.39
Common stock issued pursuant to Securities Purchase Agreement (see Note 9)	$ 5,000,000
Fair value of common stock	$ 5,400,000

Commitments and contingencies_5

Commitments and contingencies - Schedule of future payments under loan and security agreement (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Future payments under the Loan Agreement
2,019	$ 6,654
2,020	8,297
2,021	8,279
2,022	8,279
2,023	8,279
Thereafter	89,998
Total remaining payments	129,786
Less: amount representing debt discount	(721)
Less: amount representing interest	(54,588)
Total non-current debt obligation	$ 74,477	$ 39,084

Commitments and contingencies_6

Commitments and contingencies - Capital leases narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Capital Leased Assets [Line Items]
Lease term	3 years
Interest expense	$ 300	$ 200	$ 100
Total property and equipment, gross	52,395	49,871
Accumulated depreciation and amortization	2,000	3,000
Equipment under capital lease
Capital Leased Assets [Line Items]
Total property and equipment, gross	$ 7,129	$ 11,446

Commitments and contingencies_7

Commitments and contingencies - Schedule of future minimum lease payments under capital leases (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Future payments under the capital lease
2,019	$ 2,087
2,020	1,392
2,021	21
Total capital lease obligations	3,500
Less: amount representing interest	(188)
Present value of net minimum capital lease payments	3,312
Less: current portion	(1,937)	$ (2,039)
Total non-current capital lease obligations	$ 1,375	$ 3,373

Commitments and contingencies_8

Commitments and contingencies - Schedule of future payments under noncancelable unconditional purchase commitments (Details) - Service agreements and laboratory supplies $ in Thousands	Dec. 31, 2018USD ($)
Long-term Purchase Commitment [Line Items]
2,019	$ 3,040
2,020	3,040
2,021	1,440
Total	$ 7,520

Commitments and contingencies_9

Commitments and contingencies - Other commitments narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Other Commitments [Line Items]
Registration payment arrangement term	P12M
Accrued liabilities	$ 26,563	$ 22,742
Co Development Agreement
Other Commitments [Line Items]
Right of refusal fees related to acquisition agreement	3,000
Payment of refusal fees related to the acquisition agreement	1,000
Accrued liabilities	$ 2,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of shares of common stock reserved for future issuance (Details) - shares	Dec. 31, 2018	Dec. 31, 2017
Class of Stock
Common stock reserved for future issuance (in shares)	12,936,000	15,868,000
Convertible Preferred Stock
Class of Stock
Common stock reserved for future issuance (in shares)	3,459,000	3,459,000
Stock Payable Liabilities
Class of Stock
Common stock reserved for future issuance (in shares)	132,000	689,000
Payable as Contingent Consideration
Class of Stock
Common stock reserved for future issuance (in shares)	452,000	551,000
Shares of common stock subject to outstanding warrants
Class of Stock
Number of shares of common stock underlying warrants (in shares)	611,000	1,962,000
Shares of common stock subject to outstanding RSUs
Class of Stock
RSU awards issued and outstanding (in shares)	4,031,000	2,387,000
Stock incentive plans | Employee Stock Option
Class of Stock
Options issued and outstanding (in shares)	3,855,000	4,115,000
Shares available for grant under stock options plans (in shares)	118,000	2,397,000
2015 Employee Stock Purchase Plan
Class of Stock
Common stock reserved for future issuance (in shares)	277,577	308,000

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			2 Months Ended	12 Months Ended
	Aug. 31, 2018	Apr. 30, 2018	Aug. 31, 2017	Feb. 28, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Proceeds from issuance of common stock					$ 17,511	$ 74,619	$ 3,134
Common stock
Class of Stock [Line Items]
Common stock issued during period (in shares)					17,103,000		8,433,000
Common stock issued pursuant to exercise of warrants (in shares)					1,022,000	5,176,000
Private placement
Class of Stock [Line Items]
Gross proceeds from private placement			$ 73,500
Net proceeds from private placement			$ 68,900
Preferred stock to common stock conversion ratio	100.00%
Preferred stock liquidation preference per share (in dollars per share)			$ 0.001
Private placement | Series A Convertible Preferred Stock
Class of Stock [Line Items]
Number of shares sold in private placement (in shares)			3,500,000
Shares issued price per share (in dollars per share)			$ 8.50
Private placement | Common stock
Class of Stock [Line Items]
Number of shares sold in private placement (in shares)			5,200,000
Shares issued price per share (in dollars per share)			$ 8.50
Underwritten public offering
Class of Stock [Line Items]
Proceeds from issuance of common stock		$ 57,500
Net proceeds from issuance of common stock		$ 53,500
Underwritten public offering | Common stock
Class of Stock [Line Items]
Number of shares sold in private placement (in shares)		12,800,000
Shares issued price per share (in dollars per share)		$ 4.50
2018 Sales Agreement | Cowen and Company, LLC
Class of Stock [Line Items]
Percentage of commission payable on gross proceeds	3.00%
2018 Sales Agreement | Cowen and Company, LLC | Common stock
Class of Stock [Line Items]
Proceeds from issuance of common stock					$ 61,100
Net proceeds from issuance of common stock					$ 58,900
Common stock issued during period (in shares)					4,300,000
Maximum | 2018 Sales Agreement | Cowen and Company, LLC
Class of Stock [Line Items]
Proceeds from issuance of common stock	$ 75,000
CombiMatrix
Class of Stock [Line Items]
Proceeds from warrant exercises					$ 6,500
Common stock issued pursuant to exercise of warrants (in shares)					1,000,000
Subsequent event | Series A Convertible Preferred Stock | Series A convertible preferred stock converted to common stock
Class of Stock [Line Items]
Shares converted (in shares)				1,100,000
Subsequent event | Common stock | Series A convertible preferred stock converted to common stock
Class of Stock [Line Items]
Shares issued upon conversion (in shares)				1,100,000

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of outstanding warrants to purchase common stock (Details) - Common Stock	Dec. 31, 2018$ / sharesshares
Class of Warrant or Right [Line Items]
Number of shares of common stock underlying warrants (in shares)	610,875
CombiMatrix | Series F Warrants
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share) | $ / shares	$ 5.95
Number of shares of common stock underlying warrants (in shares)	408,548
Warrants issued to lender under Loan and Security Agreement
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share) | $ / shares	$ 10.27
Number of shares of common stock underlying warrants (in shares)	116,845
Warrants issued to lender under Loan and Security Agreement - 2018 Amendments
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share) | $ / shares	$ 7.02
Number of shares of common stock underlying warrants (in shares)	85,482

Stock incentive plans - Narrati

Stock incentive plans - Narrative (Details)	1 Months Ended			12 Months Ended
	Feb. 28, 2017shares	Feb. 29, 2016	Jan. 31, 2015	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)Employee$ / sharesshares	Dec. 31, 2016USD ($)$ / shares
Stock incentive plan
Stock-based compensation				$ 20,850,000	$ 19,221,000	$ 10,699,000
Additional shares reserved (in shares) | shares				12,936,000	15,868,000
Number of employees affected by the stock option and RSU modifications | Employee					14
Incremental compensation cost relating to stock option and RSU modifications						$ 300,000
Unrecognized stock-based compensation				$ 4,500,000
Expected period to recognize on a straight-line basis				1 year 9 months 18 days
Capitalized stock-based employee compensation				$ 0
Shares of common stock subject to outstanding RSUs
Stock incentive plan
Weighted-average grant date fair value (in dollars per share) | $ / shares				$ 7.46	$ 10.03	$ 9.80
Share-based compensation arrangement by share-based payment award equity instruments other than options granted in period (in shares) | shares				3,282,000
Unrecognized stock-based compensation				$ 22,600,000
Expected period to recognize on a straight-line basis				2 years 1 month 6 days
Shares of common stock subject to outstanding PRSUs
Stock incentive plan
Weighted-average grant date fair value (in dollars per share) | $ / shares						$ 6.50
Share-based compensation arrangement by share-based payment award equity instruments other than options granted in period (in shares) | shares				0	0
Unrecognized stock-based compensation				$ 0
Non-Employee Options
Stock incentive plan
Vested stock units awarded (in shares) | shares				0
2015 Plan | Shares of common stock subject to outstanding PRSUs
Stock incentive plan
Vesting period		12 months
Vested stock units awarded (in shares) | shares	352,045
Stock-based compensation					$ 400,000	$ 1,900,000
Stock incentive plans
Stock incentive plan
Vesting period				4 years
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage				25.00%
Share-based compensation arrangement by share-based payment award, vesting rights, equal monthly vesting percentage				2.08%
Stock incentive plans | Shares of common stock subject to outstanding RSUs
Stock incentive plan
Vesting period				3 years
Share-based compensation arrangement by share-based payment award equity instruments other than options granted in period (in shares) | shares				3,282,000
Stock incentive plans | Shares of common stock subject to outstanding options
Stock incentive plan
Weighted-average grant date fair value (in dollars per share) | $ / shares				$ 4.87	$ 5.82	$ 6.18
Total grant date fair value of options to purchase common stock vested				$ 5,900,000	$ 6,900,000	$ 5,600,000
Exercised, aggregate intrinsic value				$ 1,700,000	$ 2,100,000	$ 1,400,000
Stock incentive plans | First anniversary | Shares of common stock subject to outstanding RSUs
Stock incentive plan
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage				33.33%
Stock incentive plans | Second anniversary | Shares of common stock subject to outstanding RSUs
Stock incentive plan
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage				33.33%
Stock incentive plans | Third anniversary | Shares of common stock subject to outstanding RSUs
Stock incentive plan
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage				33.33%
2015 Employee Stock Purchase Plan
Stock incentive plan
Weighted-average grant date fair value (in dollars per share) | $ / shares				$ 3.26	$ 2.51	$ 2.66
Stock-based compensation				$ 1,400,000	$ 1,100,000	$ 900,000
Purchase price of common stock of the lesser of fair market value on the purchase date or the last trading day preceding the offering date (as a percent)			85.00%
Proceeds from stock plans				$ 600,000
Additional shares reserved (in shares) | shares				277,577	308,000
Minimum | 2010 Plan
Stock incentive plan
Employees holding voting rights of all classes of stock (as a percent)				10.00%
Exercise price of options on common stock (as a percent)				110.00%
Maximum | 2010 Plan
Stock incentive plan
Term of options granted				10 years

Stock incentive plans - Schedul

Stock incentive plans - Schedule of activity under stock incentive plans (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Shares of common stock subject to outstanding RSUs
Activity under the plan
Units granted (in shares)	(3,282)
Units cancelled (in shares)	340
Stock incentive plans | Shares of common stock subject to outstanding options
Activity under the plan
Shares available for grant, beginning balance (in shares)	2,397
Stock options outstanding, beginning balance (in shares)	4,115
Additional shares reserved (in shares)	754
Options granted (in shares)	260
Option cancelled (in shares)	(169)
Options exercised (in shares)	(351)
Shares available for grant, ending balance (in shares)	118	2,397
Stock options outstanding, ending balance (in shares)	3,855	4,115
Weighted- Average Exercise Price
Balance at the beginning of the period (in dollars per share)	$ 8.51
Options granted (in dollars per share)	8.50
Options cancelled (in dollars per share)	9.35
Options exercised (in dollars per share)	7.73
Balance at the end of the period (in dollars per share)	$ 8.54	$ 8.51
Additional information
Exercisable (in shares)	2,737
Exercisable, weighted-average exercise price (in dollars per share)	$ 8.27
Weighted-average remaining contractual life	6 years 9 months 18 days	7 years 7 months 6 days
Exercisable, weighted-average remaining contractual life	6 years 4 months 24 days
Aggregate intrinsic value	$ 9,927	$ 5,128
Exercisable, aggregate intrinsic value	$ 7,787
Vested and expected to vest
Number of options (in shares)	3,710
Weighted-average exercise price (in dollars per share)	$ 8.52
Weighted-average remaining contractual life	6 years 9 months 18 days
Aggregate intrinsic value	$ 9,626
Stock incentive plans | Shares of common stock subject to outstanding RSUs
Activity under the plan
Units granted (in shares)	(3,282)
Units cancelled (in shares)	340

Stock incentive plans - Summary

Stock incentive plans - Summary of RSU activity (Details) - Shares of common stock subject to outstanding RSUs - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares
Balance at the beginning of the period (in shares)	2,387
Granted (in shares)	3,282
Vested (in shares)	(1,298)
Cancelled (in shares)	(340)
Balance at the end of the period (in shares)	4,031	2,387
Weighted-Average Grant Date Fair Value
Balance at the beginning of the period (in dollars per share)	$ 9.91
Granted (in dollars per share)	7.46	$ 10.03	$ 9.80
Vested (in dollars per share)	8.84
Canceled (in dollars per share)	8.84
Balance at the end of the period (in dollars per share)	$ 8.35	$ 9.91

Stock incentive plans - Sched_2

Stock incentive plans - Schedule of assumptions used in determination of fair value of options (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Non-Employee Options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Expected volatility			76.92%
Non-Employee Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Expected term (in years)		8 years 4 months 28 days	6 years 3 months
Expected volatility		69.90%
Risk-free interest rate		1.83%	1.55%
Non-Employee Options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Expected term (in years)		8 years 9 months 29 days	10 years
Expected volatility		78.70%	0.00%
Risk-free interest rate		2.04%	2.37%
Employees and directors stock options | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Expected term (in years)	6 years	6 years 10 days	6 years 10 days
Expected volatility	59.58%	72.64%	71.42%
Risk-free interest rate	2.80%	2.01%	1.37%
2015 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Expected term (in years)	15 days	15 days	15 days
Expected volatility	71.66%	52.50%	66.31%
Risk-free interest rate	2.09%	1.23%	0.50%

Stock incentive plans - Stock-b

Stock incentive plans - Stock-based compensation expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Stock-based compensation
Total stock-based compensation expense	$ 20,850	$ 19,221	$ 10,699
Cost of revenue
Stock-based compensation
Total stock-based compensation expense	2,960	2,093	1,353
Research and development
Stock-based compensation
Total stock-based compensation expense	7,017	6,158	4,976
Selling and marketing
Stock-based compensation
Total stock-based compensation expense	4,887	3,956	1,709
General and administrative
Stock-based compensation
Total stock-based compensation expense	$ 5,986	$ 7,014	$ 2,661

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Contingency [Line Items]
Corporate tax rate		21.00%	34.00%	34.00%
Provisional amount related to the remeasurement of certain deferred tax assets and liabilities	$ 48,800		$ 48,800
Increase in valuation allowance		$ 26,300	2,000	$ 33,400
Net operating loss carryforwards change in ownership percentage minimum		50.00%
Unrecognized tax benefits	16,375	$ 16,375	$ 10,561	$ 7,791	$ 11,429
Federal
Income Tax Contingency [Line Items]
Net operating loss carryforwards	318,700	$ 318,700
Number of tax years open for examination		3 years
California
Income Tax Contingency [Line Items]
Number of tax years open for examination		4 years
Research and development | Federal
Income Tax Contingency [Line Items]
Tax credit carryforwards	9,000	$ 9,000
Research and development | California
Income Tax Contingency [Line Items]
Tax credit carryforwards	7,400	7,400
State
Income Tax Contingency [Line Items]
Net operating loss carryforwards	134,300	134,300
Begins to expire 2030 | Federal
Income Tax Contingency [Line Items]
Net operating loss carryforwards	277,300	277,300
No expiration date | Federal
Income Tax Contingency [Line Items]
Net operating loss carryforwards	$ 41,400	$ 41,400

Income Taxes - Schedule of comp

Income Taxes - Schedule of components of loss before income taxes by U.S. and foreign jurisdictions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
United States	$ 132,194	$ 124,108	$ 99,793
Foreign	(39)	1,128	463
Total	$ 132,155	$ 125,236	$ 100,256

Income Taxes - Schedule of co_2

Income Taxes - Schedule of components of the provision for income taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current:
Foreign	$ 62	$ 0	$ 0
Total current benefit for income taxes	62	0	0
Deferred
Federal	(2,862)	(1,704)	0
State	0	(152)	0
Total deferred benefit for income taxes	(2,862)	(1,856)	0
Total income tax benefit	$ (2,800)	$ (1,856)	$ 0

Income Taxes - Schedule of reco

Income Taxes - Schedule of reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense
U.S. federal taxes at statutory rate	21.00%	34.00%	34.00%
State taxes (net of federal benefit)	5.20%	3.30%	1.40%
Stock-based compensation	(0.70%)	(1.10%)	(1.70%)
Research and development credits	(2.70%)	0.00%	0.00%
Non-deductible expenses	(0.60%)	0.00%	0.20%
Foreign tax differential	0.00%	(0.30%)	(0.20%)
Other	0.00%	0.00%	1.10%
Change in valuation allowance	(25.50%)	(34.40%)	(34.80%)
Change in deferred—Tax Reform	0.00%	(39.00%)	0.00%
Change in valuation allowance—Tax Reform	0.00%	39.00%	0.00%
Total	2.10%	1.50%	0.00%

Income Taxes - Schedule of net

Income Taxes - Schedule of net deferred tax assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforwards	$ 76,972	$ 70,825
Tax credits	15	15
Revenue recognition differences	47,650	29,819
Accruals and other	7,262	5,544
Gross deferred tax assets	131,899	106,203
Valuation allowance	(121,954)	(95,687)
Total deferred tax assets	9,945	10,516
Deferred tax liabilities:
Property and equipment	(9,945)	(10,516)
Total deferred tax liabilities	(9,945)	(10,516)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Schedule of re_2

Income Taxes - Schedule of reconciliation of unrecognized tax benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Unrecognized tax benefits, beginning of period	$ 10,561	$ 7,791	$ 11,429
Gross increases—current period tax positions	5,686	2,552	782
Gross increases (decreases)—prior period tax positions	128	218	(4,420)
Unrecognized tax benefits, end of period	$ 16,375	$ 10,561	$ 7,791

Net loss per common share - Sch

Net loss per common share - Schedule of earnings per share, basic and diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Net loss	$ (29,841)	$ (31,723)	$ (31,671)	$ (36,120)	$ (40,493)	$ (27,402)	$ (28,557)	$ (26,928)	$ (129,355)	$ (123,380)	$ (100,256)
Shares used in computing net loss per share, basic and diluted (in shares)									66,747	46,512	33,176
Net loss per share, basic and diluted (in dollars per share)									$ (1.94)	$ (2.65)	$ (3.02)

Net loss per common share - S_2

Net loss per common share - Schedule of antidilutive securities excluded from computation of earnings per share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	12,019	11,982	5,968
Shares of common stock subject to outstanding options
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	3,855	4,115	4,491
Shares of common stock subject to outstanding warrants
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	611	1,962	0
Shares of common stock subject to outstanding RSUs
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	4,031	2,387	892
Shares of common stock subject to outstanding PRSUs
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	0	530
Shares of common stock pursuant to ESPP
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	63	59	55
Shares of common stock underlying Series A convertible preferred stock
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	3,459	3,459	0

Geographic information - Schedu

Geographic information - Schedule of revenue by country (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Geographic information
Total revenue	$ 45,356	$ 37,366	$ 37,306	$ 27,671	$ 25,399	$ 18,148	$ 14,336	$ 10,338	$ 147,699	$ 68,221	$ 25,048
United States
Geographic information
Total revenue									138,239	62,446	20,758
Canada
Geographic information
Total revenue									4,206	3,226	2,526
Rest of world
Geographic information
Total revenue									$ 5,254	$ 2,549	$ 1,764

Selected Quarterly Data (Unau_3

Selected Quarterly Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Total revenue	$ 45,356	$ 37,366	$ 37,306	$ 27,671	$ 25,399	$ 18,148	$ 14,336	$ 10,338	$ 147,699	$ 68,221	$ 25,048
Cost of revenue	21,141	20,441	20,447	18,076	17,049	13,274	10,490	9,329	80,105	50,142	27,878
Loss from operations	(25,904)	(30,110)	(30,068)	(36,475)	(34,891)	(30,976)	(28,075)	(27,337)	(122,557)	(121,279)	(100,183)
Net loss	$ (29,841)	$ (31,723)	$ (31,671)	$ (36,120)	$ (40,493)	$ (27,402)	$ (28,557)	$ (26,928)	$ (129,355)	$ (123,380)	$ (100,256)
Net loss per share, basic and diluted (in dollars per share)	$ (0.40)	$ (0.45)	$ (0.47)	$ (0.66)	$ (0.78)	$ (0.57)	$ (0.66)	$ (0.64)	$ (1.94)	$ (2.65)	$ (3.02)
Debt extinguishment costs									$ 4,609	$ 0	$ 0
Secured Debt | Loan and Security Agreement
Debt extinguishment costs	$ 5,300

Uncategorized Items - nvta-10k.

Label	Element	Value
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 11,241,000